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White matter lesions (WML) are the white matter abnormalities 
characterized by myelin rarefaction, axonal loss, glia activation in the white 
matter of the cerebral hemisphere. WML are one of most common vascular 
pathologies of vascular cognitive impairment (VCI). Sphingolipids, as one of 
three major classes of lipids found in cerebral myelin membrane, are 
important structure components of white matter and some of the bioactive 
sphingolipids are also involved in various physiological and pathological 
processes as signaling mediators. Sphingosine-1-phosphate (S1P) is a well-
known bioactive sphingolipid molecule. It is derived from phosphorylation 
of sphingosine by sphingosine kinase (SphK). Previous studies have 
demonstrated that SphK and S1P altered in hypoxia and the S1P signaling 
pathway is involved in regulating oligodendroglial lineage cell survival, 
proliferation, membrane dynamics and differentiation. Growing evidence 
suggests that the failure to form new myelin sheaths due to disruption of 
OPC differentiation is one factor underlying chronic white matter damage.  
However, the sphingolipid changes of hypoperfusion induced-WML are not 
known. In addition, it has not been revealed whether SphK and S1P signaling 
pathway is involved in the ischemic WML.  
In this study, we demonstrated a lipidome of cerebral WML by LC-
MS/MS analysis in a mouse bilateral carotid artery stenosis (BCAS) model 
of chronic cerebral hypoperfusion, showing a profile of individual lipid 
molecules belonging to ceramide, sphingomyelin, glycoceramide, 
sphingosine and S1P. Amounts of phospholipids including 
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phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylglycerol (PG), and 
phosphatidylinositol (PI), lysoPC (LPC), lysoPE (LPE) and cholesterol were 
measured. Overall content reduction in glycosphingolipids and sphingosine 
and overall increase of S1P, PS and PG were found in white matters of 
BCAS mice compared with sham-operated ones. Besides, BCAS induced 
composition alteration of sphingolipid in white matters, in which very long 
acyl chain-sphingolipids reduced whereas long acyl chain-sphingolipid 
elevated. Cholesterol levels in white matters remained unchanged in BCAS 
mice. When SphK, S1P as well as markers of WML, hypoxia and 
oligodendrocyte progenitor cells (NG2+) were measured in WML, it was 
found that in BCAS mice, hypoxia inducible factor (HIF)-1α, Sphk2, S1P, 
and NG2 were up-regulated in association with the accumulation of WML. 
Significantly, a SphK inhibitor SKI-II showed partial reversal of SphK2, S1P 
and NG2 elevation and amelioration of WML. In an in vitro model of 
hypoxia, SKI-II reversed the suppression of OPC differentiation induced by 
hypoxia indicating that the hypoxia inhibits OPC differentiation via S1P.  
In conclusion, this study suggests a mechanism for hypoperfusion-
associated WML involving various structural and bioactive lipid aberrations 
which may cause demyelination and HIF-1α-SphK2-S1P-mediated 
disruption of OPC differentiation, and proposes the SphK signaling pathway 
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CHAPTER 1 INTRODUCTION 
1.1 Vascular cognitive impairment 
1.1.1 Definition of VCI 
Cognitive impairment is a prominent health issue among older people. 
The prevalence of dementia is reported to be around ~5-7% in people older 
than 65 years (O'Brien et al. 2003) (Kalaria et al. 2008). As the second most 
common cause, cerebrovascular diseases including stroke, subcortical 
ischemic injury, and small-vessel disease, account for ~30% of the cases 
(Kalaria et al. 2008). Recently, the term “Vascular cognitive impairment” 
(VCI) has been designated as a syndrome with evidence of clinical stroke or 
subclinical vascular brain injury and cognitive impairment affecting at least 
one cognitive domain to describe the entire range of cognitive disorders from 
mild cognitive impairment to fully developed vascular dementia (VaD) 
(Gorelick et al. 2011). 
1.1.2 Vascular neuropathological substrates 
VCI includes a combination of variegated brain lesions in association 
with multiple neuropathological manifestations. The lesions may vary in size, 
number and location.  Besides they also frequently observed in older people 
without cognitive impairments or in Alzheimer disease as well. These 
complexities add to difficulties in understanding the pathology underlying 
VCI.   
1.1.2.1 Cerebral infarcts  
Cerebral infarcts are tissue loss observed by naked eye or under the 
microscope in discrete brain regions (Gorelick et al. 2011). Historically, 
multiple infarcts in subcortical areas mainly white matter and basal ganglia 
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are thought to be the most common neuropathology in VCI (Ferrer 2010). 
Characteristics of multiple infarcts could be variable. Cerebral infarcts are 
common in older people with and without dementia. For example, White et 
all reported more than half of the autopsied decedents had brain infarcts in a 
study involved 363 aged Japanese-American men from the Honolulu-Asia 
Aging Study (White et al. 2005). Another study by MRC-CFAS in a large 
unselected, community-based elderly (70-103 years) UK population reported 
that infarcts were observed in 31% of the total 209 autopsy brain samples 
(Neuropathology Group. Medical Research Council Cognitive and Aging 
2001). Sonnen et al evaluated 221 autopsies from an ongoing longitudinal, 
population-based study of brain aging and dementia (3400 people >65 years) 
and reported 33% of the 221 autopsies have microinfarcts in the brain. It is 
difficult to determine the threshold of necessary volume or number for VCI 
or VaD, since reported values varied significantly (Vinters et al. 2000) 
(Tomlinson, Blessed, and Roth 1970; Zekry et al. 2002). Increased volume 
and larger number of infarcts are generally thought to be associated with a 
greater likelihood of dementia (Neuropathology Group. Medical Research 
Council Cognitive and Aging 2001; Sonnen et al. 2007; Schneider et al. 
2003). In addition, the location of infarcts also contributes to the inconsistent 
correlations (Ferrer 2010). 
1.1.2.2 Lacunes 
Lacunes are small cavities filled with cerebrospinal fluid in basal ganglia 
or white matter (Wardlaw 2008). They possibly arise from obstruction of the 
trunk of a perforating artery or small ramifications perforating artery 
followed by progressive hypoxia/ischemia (Wardlaw 2008). Haemorrhages 
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and dilatation of the perivascular space may also contribute to some lacunes 
(Ferrer 2010). 
Lacunes are frequently seen in VCI (Neuropathology Group. Medical 
Research Council Cognitive and Aging 2001; Park et al. 2014). Gold et al. 
has also reported that thalamic and basal ganglia lacunes were associated 
with cognitive decline in subcortical ischemic vascular dementia (Gold et al. 
2005). In addition, Lacunar stroke that characterized by periventricular white 
matter and basal ganglia lacunes has been reported to cause cognitive decline 
in 83% of the patients (Aharon-Peretz, Daskovski, and Mashiach 2002). 
1.1.2.3 White matter lesions 
White matter lesions (WML), also called leukoaraiosis, is the white 
matter abnormalities characterized by myelin rarefaction, axonal loss,  glia 
activation in the white matter of the cerebral hemisphere, and dilatation of 
periventricular space (Pantoni and Garcia 1995). WML is frequently 
observed in 50% to 98% of community elderly (Xiong and Mok 2011) and in 
64% to 100% of patients with vascular dementia (Pantoni and Garcia 1995). 
Contribution of WML to cognitive impairment has been well-documented 
(Gold et al. 2005) (de Groot et al. 2002) (de Groot et al. 2001) in clinical-
pathological studies. Besides, animal models of white matter lesions induced 
by hypoperfusion also demonstrated cognitive deficits (Shibata et al. 2004; 
Shibata et al. 2007). 
Subcortical ischemic vascular dementia (SIVD) is a subtype of VCI. 
Cerebral small-vessel disease is the main cause of SIVD (Roman et al. 2002). 
WML is one of the primary types of brain lesion in SIVD. Small vessel 
disease including arteriolosclerosis, arteriolar hyalinosis and fibrinoid 
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deposit induces microvascular changes in the white matter, resulting in 
hypoperfusion.  
Clinical-pathological studies have found that these three types of cerebral 
lesions didn't occur alone in VCI. According to MRC CFAS study 
(Neuropathology Group. Medical Research Council Cognitive and Aging 
2001), small-vessel disease characterized by WML is the most common 
pathology in a community-based elderly UK population (70-103 years), 
observed in 69% of subjects. Ccombined ischemic pathologies in the same 
brain were present in 39% subjects, 94% of whom had WML as one of the 
components. Another study by Gold et al (Gold et al. 2005) has also reported 
demyelination often co-existed in 95% of the cases with lacunes. 
1.1.2.4 Vascular pathologies in Alzheimer’s disease 
Alzheimer’s disease (AD), the most common form of dementia, is 
characterized by neuropathological hallmarks of amyloid angiopathy and 
neurofibrillary tangles. It accounts for 50-60% of the dementia (Kalaria, 
Maestre, and Arizaga 2008). Increasing evidence has shown that vascular 
pathologies also occur in AD. A population-based autopsy study reported 
that vascular pathologies were observed in 20% of the AD patients 
(Knopman et al. 2003). Another autopsy study also reported that minor and 
moderate vascular pathology in ~40% of AD brains which is about twice as 
frequent as in controls (Jellinger and Attems 2005). It is evident that vascular 
pathologies may be a contributing cause of cognitive decline in AD 
(Schneider et al. 2004). Conversely, amyloid deposition in cerebral blood 




1.1.3 Risk factors  
1.1.3.1 Demographic factors 
Age is a substantial risk factor for VCI. Prevalence increased steeply 
with increasing age.  One population based-study in middle-aged people in 
the UK has reported that the prevalence of VaD were 6.6/100 000, 32.6/100 
000 and 38.7/100 000 respectively for age range of 50-54, 55-59, and 60-
64(Harvey, Skelton-Robinson, and Rossor 2003). The prevalence of VaD 
increases exponentially in people after 65 years old, with a range of 0.6-2.1% 
(Gorelick et al. 2011; Kalaria, Maestre, and Arizaga 2008). Gender 
difference is controversial. Some studies observed a higher incidence of VaD 
in men than in women (Rocca et al. 1991) (Ruitenberg et al. 2001). Whereas, 
some reported no difference (Andersen et al. 1999). Besides, lower 
educational level is thought to increase the risk of VaD (Gorelick 1997).  
1.1.3.2 Genetic factors 
The genetic factors include cerebral autosomal dominant arteriopathy 
with subcortical infarct and leukoencephalopathy (CADASIL) and 
apolipoprotein E (apoE) ε4. CADASIL is a cerebrovascular small-vessel 
disease caused by mutations of the Notch3 gene (Joutel et al. 1996). The 
pathologies are characterized with diffuse WML and deep lacunes (Chabriat 
et al. 2009), which can induce recurrent strokes, or VCI cognitive 
impairment in young people. Several genome-wide studies have indicated 
the association of apoE and VaD (Debette et al. 2010) (Ikram et al. 2009), 




1.1.3.3 Life style factors 
Long-term regular physical activity has been reported to strongly 
associate with less cognitive decline and less VaD (Ravaglia et al. 2008). 
Smoking is a well-studied risk factor for cognitive decline and 
cardiovascular system (Anstey et al. 2007). The association between obesity 
and VCI seemed to be variable with age.  It is reported that obesity increased 
the risk of VCI in people <50 years old while reduced the risk in people >65 
years old (Fitzpatrick et al. 2009). A 32-year prospective study has indicated 
a dementia-associated weight loss (Stewart et al. 2005) which may explain 
the different effect of BMI on VCI. Other possible life style factors include 
diet, alcohol consuming, and social support, but they are controversial 
(Gorelick et al. 2011) 
1.1.3.4 Atherogenic factors  
Atherogenic factors including hypertension, diabetes, 
hypercholesterolemia and elevated hyperhomocysteinaemia have been 
considered to increase the risk of VCI. Midlife hypertension is considered a 
risk factor for cognitive impairment in later life (Launer et al. 1995). This, 
however, still remains to be clarified (Gorelick et al. 2011). Several studies 
have shown that chronic hyperglycemia and diabetes are associated with VCI 
(Saczynski et al. 2008) (Cukierman-Yaffe et al. 2009). Patients with 
subcortical vascular white matter lesions caused by small vessel disease 
exhibited surprisingly high concentrations of homocysteine compared with 
controls and even to patients with cerebral macroangiopathy (Fassbender et 
al. 1999). Hyperhomocysteinaemia is an independent risk factor for SIVD, 
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particularly ischemic WML which may be associated with 
endothelial dysfunction (Hassan et al. 2004). 
High cholesterol level in midlife has been reported to strongly increase 
the risk for cognitive decline and VaD in later life (Solomon et al. 2009). 
Similar to hypertension, the risk of higher cholesterol level in older people is 
inconsistent (Mielke et al. 2005). 
1.1.4 Diagnosis  
1.1.4.1 Diagnostic criteria 
Several diagnostic criteria have been proposed for VCI.  NINDS-AIREN 
criteria were devised in the early 90’s and have been used in research as 
diagnostic tools to operationalize symptoms of the VaD (Roman et al. 1993). 
Modification of NINDS-AIREN has also been proposed for clinical trials 
(Erkinjuntti et al. 2000). These criteria were subsequently criticized for being 
mainly based on features of AD and memory may not necessarily be 
impaired in VCI and VaD. More recently, criteria for VCI from the 
American Heart Association/American Stroke Association (Gorelick et al. 
2011) and the criteria for vascular cognitive disorders (VCD)  from the 
VasCog society have been proposed (Sachdev et al. 2014). These criteria 
share three core elements: (1) presence of cognitive impairment, (2) presence 
of cerebral vascular pathologies and (3) a causal link between the two.  
1.1.4.2 Cognitive evaluation 
Vascular risk factors should be identified, including history of 
hypertension, diabetes, physical activity and smoking status as discussed 
above (Biessels 2015). Besides, manifestations of ischemic heart disease, 
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congestive heart failure, peripheral vascular disease, and stroke should be 
recorded. Family history might also be of importance as well (Biessels 2015).  
Since VCI may include deficits in all cognitive domains especially 
executive dysfunction such as slowed information processing, reduced 
ability to shift from one task to another, and deficits of working memory 
(Hachinski et al. 2006), cognitive testing covering at least 4 domains should 
be assessed: executive/attention, memory, language and visuospatial 
functions (Gorelick et al. 2011). In addition, Behavioral changes such as 
mood and character changes and other symptoms of neurological deficits, 
gait and balance problems should also be taken account (Biessels 2015).  
Rapid advances in neuroimaging techniques have provided powerful tool 
for evaluating vascular pathologies such as WML, brain atrophy and 
macroscopic infarcts. WML characterized by myelin rarefaction, axonal loss, 
glia cell activation in the white matter of the cerebral hemisphere, and 
dilatation of periventricular space (Pantoni and Garcia 1995) appears as 
hyperintense (WMH) on MRI FLAIR and T2/proton density-weighted 
images (Pantoni et al. 1999). WMH is highly correlated with ischemic WML 
but not AD pathology (Wardlaw et al. 2013). In addition, WML detected by 
WMH could be the only neuroimaging observation in younger people, and 
thus is essential for the diagnosis of CADASIL (Chabriat et al. 2009).  
1.1.5 Therapeutic implications 
Although increasing numbers of studies have been conducted in VCI or 
VaD over the past decades, there are no known curative therapies for VCI. 
Symptomatic treatment and management of vascular risks and have been 
primary approaches.  
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1.1.6 Symptomatic treatment 
Many trials to test drugs approved for AD have failed. Evidence indicates 
that cholinesterase inhibitors may be promising in VaD (Erkinjuntti et al. 
2004). Donepezil has shown modest cognitive benefit in pure VaD of 24-
week (Black et al. 2003) (Wilkinson et al. 2003) and an extra 30-week 
extension study (Wilkinson et al. 2010). Galatamine may be beneficial for 
mixed dementia (Erkinjuntti et al. 2002). Other agents including vasodilators 
and antioxidants are disappointing (O'Brien et al. 2003). 
1.1.6.1 Prevention 
Lowering blood pressure in middle-aged and young-elderly can be 
beneficial for the prevention of late-life dementia by reducing the risk of 
stroke (Forette 2003; O'Brien et al. 2003). Besides, physical activity might be 
useful for the prevention (Sofi et al. 2011). The efficacy of controlling other 
risk factors such as cholesterol and diabetes are not well established 
(Gorelick et al. 2011). 
Recently, a randomized double-blind, parallel, placebo-controlled trial 
involving 359 patients on a homocysteine-lowering  therapy by daily B-
vitamin supplementation with  vitamins B12 and B6 for 2 years has 
suggested that there is a significant reduction in white matter hyperintensities 
volume change in sub-analysis of patients with MRI evidence of severe 




1.2 Mechanisms of white matter lesions 
Populations all over the world especially in developed economies are 
rapidly ageing due to advances in medicine helping more people to live 
longer. According to WHO, there were ~ 8% of global population was >65 
years old by 2010, and it will increase to ~15% with ~2 billion by 
2050(WHO 2015). While celebrating the advances in medicine helping 
people to live longer, we should also notice that 15-35% of older people to 
some extent experience disabilities in daily living (WHO 2015). Cognitive 
impairment in older people significantly affects the quality of their late-life 
and increases the burdens of both the family and society. Unfortunately, 
there are currently no curative therapies for both AD and VCI, the two most 
common types of cognitive impairments due to lacking of clear 
understanding of the pathophysiological mechanisms. Since WML is one of 
most common vascular pathologies in VCI and it has an essential role in 
diagnosis of VCI, it is of great importance to investigate the 
pathophysiological mechanisms in vascular WML. It is characterized by 
myelin rarefaction, axonal loss, glia activation and oligodendrocytes 
apoptosis. It is widely occurred and closely correlated with cognitive 
impairment in elderly people. Although, growing evidence has shown that it 




 Figure 1.1 The structure of the myelin sheath and schematic 
representation of the major myelin components. 
The myelin sheath forms from flattened cytoplasmic processes from the 
oligodendrocyte. Compacted cytoplasm forms the major dense line and close 
apposition of the membrane layers forms the intraperiod line. The myelin 
bilayer has an asymmetric lipid composition. Outer layer of the membrane 
contains glycosphingolipids such GalCer and sulfatides, while inner layer 
contains PI and PS. MBP is localized to cytoplasmic leaflets of the 
membrane. PLP is a transmembrane protein localized to the membrane 
bilayer. The figure is adapted from (Greer 2013) and(Aggarwal, Yurlova, 
and Simons 2011). 
 
1.2.1 Composition of cerebral white matters  
Cerebral white matters form the bulk of the deep parts of the brain, 
beneath the grey matter layer of the cortex. It consists mostly of glial cells 
and myelinated axons which give it the characteristic white colour. 
Oligodendrocytes send out sail-like extensions of their cytoplasmic 
membrane, wrapping up to multiple layers around the axon of an adjacent 
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neuron to form the myelin sheaths (Figure 1.1). Compacted cytoplasm forms 
the major dense line and close apposition of the membrane layers forms the 
intraperiod line (Greer 2013). Myelin is the essential component of white 
matter in the CNS, accounting for 40–50% on a dry weight basis (Baumann 
and Pham-Dinh 2001). Due to its characteristic electrical insulation, myelin 
facilitates impulse conduction while saving energy and space (Waxman 
2004). The membrane composition of the myelin sheath is unique with a 
high proportion of lipid (~70% of dry mass) relative to protein (~30%), while 
the lipid to protein ratio is around 1:1 and 1:3 for most plasma and 
mitochondrial membranes, respectively (Petty 1993). An intimate 
understanding of myelin and its major components is required in order to 
study white matter pathologies. 
1.2.1.1 Lipid composition in white matter and myelin 
Nervous tissues are very rich in lipids among other tissues of the body. 
Lipids in adult cerebral white matter are about 1.6-fold of that in grey 
matters due to the presence of myelin (O'Brien and Sampson 1965). 
Cholesterol, phospholipids (glycerophospholipid), and sphingolipid are the 
three major lipid classes found in white matters and myelin.  
1.2.1.1.1 Fatty acids   
Fatty acids consist of a long hydrocarbon chain and a carboxylic acid 
group. Fatty acids in CNS appear primarily as esterified components of 
complex lipids as N-acyl groups of sphingolipids or O-acyl groups of 
glycerophospholipids. Variations in the structure of fatty acids, specifically 
the chain length and the number of double bonds, give rise to numerous 
distinct lipid molecules with distinct structural and functional roles. Fatty 
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acids with 14 to 24 carbon atoms and zero to six double bonds are the more 
abundant ones that could be observed in the brain. Figure 1.2 shows the 
chemical structures of two typical fatty acids with different hydrocarbon 
chains, stearic acid (C18:0) and nervonic (C24:1). These two are the most 
common acyl chain donors of   sphingolipids in the brain. Most of these fatty 
acids contain an even number of carbon atoms while fatty acids with an odd 
number of carbon atoms can be observed in small amounts as well. The 
composition of fatty acids of lipids varies in different subclasses of lipids. 
Because of the accumulation of lipids during the periods of brain 
development and maturation, the overall content of fatty acids are increasing 
correspondingly, while the fatty acid composition remains relatively 
unchanged (Sastry 1985).  Nevertheless, it has been reported that the fatty 
acid pattern of sphingomyelin shows significant alteration during the early 
brain development (Svennerholm and Vanier 1973).  
Fatty acids can be taken up by the brain from the circulating blood or 
synthesized de novo in the brain. This process has been reviewed decades 
before (Olson 1966). Simply, the synthesis starts with the ATP-dependent 
carboxylation of acetyl-CoA into malonyl-CoA by carboxylase. Then the 
malonyl-CoA and an acetyl-CoA bind to a fatty acid synthase complex 
which contains an acyl carrier protein (ACP) domain and condensed to form 
acetoacetyl-ACP. Acetoacetyl-ACP was reduced to butryl-ACP by two 
NADPH2. Butyl-ACP would then condense with another malonyl-CoA and 
repeat the reduction steps to produce growing fatty acid chain. Two carbons 
will be added to the acyl intermediates in each circle. When the fatty acid 
becomes C16 long, it will be released from the enzyme complex and produce 
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a palmitate. Since the fatty acids in CNS usually consist of long or very long 
acyl chain, most of palmitic acids will be subjected to chain elongation 
process in the mitochondria or microsomes in which C2 units will be added 
from acetyl CoA involving either NADH or NADPH (Sastry 1985).   
 
Figure 1.2 Chemical structure of Stearic acid and Nervonic acid. 
Stearic acid (C18:0) and nervonic acid (C24:1) are common fatty acids in 
nerve tissues. Sphingolipids that contain C18 or C24 with no or one C=C 
double bond in the acyl chain are most commonly seen in white matters.  
 
1.2.1.1.2 Cholesterol 
Cholesterol is the major sterol and accounts for ~20% of total lipids in 
the adult white matters (O'Brien and Sampson 1965). As shown in Figure 
1.3A, it has a steroid linked with a hydrocarbon tail at its end and a hydroxyl 
group attached at the other end. During brain developing, especially the 
myelinating period, cholesterol is largely synthesized in the brain (Sastry 
1985). Cholesterol plays an important role in lipid raft assembly and in 
regulating the biophysical properties of cellular membrane (Simons and 
Ikonen 2000).  
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 Figure 1.3 Representative chemical structures of three major myelin 
lipid classes 
A, Cholesterol B,  Phospholipid including phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylglycerol (PG),  and phosphatidylinositol (PI) C, Sphingolipid 





Phospholipids are derived from glycerol, in which the glycerol backbone 
is attached by fatty acids, a phosphate and a head group attached to the 
phosphate (Berg JM 2002). As shown in Figure 1.3.B, the head group, 
commonly include choline, ethanolamine, the amino acid serine, glycerol, 
and inositol, is linked to the phosphate via an ester bond to form several 
phospholipid subclasses, namely phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylglycerol (PG), and phosphatidylinositol (PI), respectively. The 
two fatty acid chains are hydrophobic while the phosphoryl head group is 
hydrophilic and thus the phospholipid molecule is amphipathic. Total 
phospholipids account for about 30~40% of the total lipids in cerebral white 
matters and myelin (O'Brien and Sampson 1965) and PE, PC and PS are the 
three most abundant subclasses. Phospholipids are major structural 
components of membrane bilayers (van Meer, Voelker, and Feigenson 2008). 
Some of them are also bioactive lipids such as PS and PG (Kim, Huang, and 
Spector 2014) (Schenkel and Bakovic 2014). Lysophospholipids are 
derivatives of phospholipids where one acyl chain is missing and only one 
hydroxyl group of glycerol backbone is acylated (D'Arrigo and Servi 2010). 
Lysophospholipids are found only in small amounts in cellular membranes, 
acting as bioactive lipids in regulating various signalling processes (D'Arrigo 
and Servi 2010).  
1.2.1.1.4 Sphingolipids 
Sphingolipids are a class of complex lipids that contain a sphingoid base 
as its backbone (Figure 1.3C). Modification of this basic structure gives rise 
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to a vast family of sphingolipids including sphingosine, ceramides (Cer), 
sphingomyelin (SM), and glycosphingolipids as the major subclasses of 
sphingolipids. These subclasses of sphingolipids are interconvertible in 
sphingolipids metabolism (Hannun and Obeid 2008). Sphingolipids are 
components of all membranes but they are particularly abundant accounting 
for ~30% of the total lipids in white matters. 1.2.1.1.4.1 Ceramide 
As shown in Figure 1.4, ceramides are synthesized do novo firstly from 
serine and palmitate to form the 3-keto-dihydrosphingosine through the 
action of palmitoyl transferase (SPT) (Sastry 1985). Then 3-
ketohydrosphingosine is reduced to dihydrosphingosine. Ceramide synthases 
(CerS) then introduce a fatty acyl chain that may vary in the number of 
carbons (mainly 16-26C in the brain) to the C-2 amino group using acyl-CoA 
as substrate, producing the dihydroceramides. Ceramide is formed by 
desaturation via desaturase. Six members of CerS have been identified, 
namely CerS1-6 (Imgrund et al. 2009). Each of them has its special 
preference for fatty acid residue. It has been shown that CerS2 and CerS4 
prefer very long chain (VLC) acyl-CoAs (C22-24 and C20 respectively), 
while CerS5 and CerS6 show a preference for shorter acyl-CoAs (C14-16). 
CerS1 uses long chain (LC) acyl-CoA (18C) mainly in neurons. CerS3 may 
be related with ultralong-chain (>C26) in the skin (Zigdon et al. 2013) 
(Jennemann et al. 2012). Ceramide is the central hub of sphingolipid 
metabolism. Glycosphingolipids, sphingomyelin and sphingosine are the 




 Figure 1.4 De novo synthesis of ceramide and sphingolipids metabolism 
The de novo synthesis of ceramide is shown in the dotted box: Palmiate-CoA 
and serine condensation to form the dehydrosphingosine, followed by 
reduction to dihydrosphingosine. Then CerS adds an acyl chain to form 
dihydroceramide which is desaturated to become ceramide. Ceramide is 
considered to be the hub of sphingolipid metabolism, in which it can be 
converted to sphingomyelin and glycoceramide or more complex 
glycosphingolipids by SMS and GCs respectively. CDase uses ceramide as 
substrate to synthesize sphingosine that can be phosphorylated to S1P further. 
S1P lyase degrades S1P to ethanolamine phosphate and hexadecenal, which 
is the only exit point of sphingolipid metabolism. Abbreviations:  CerS, 
ceramide synthase; CDase, ceramidase; SMS, sphingomyelin synthase; 
SMase, sphingomyelinase; GCs, glycosyl ceramide synthases; GCase, 
glycosyl ceramidase; S1P, sphingosine-1-phosphate; Sphk, sphingosine 




Glucosylation and galactosylation of ceramide by glucosyl or galactosyl 
ceramide synthases (GCs) lead to the formation of glucosylceramide (GluCer) 
and galactosylceramide (GalCer), which are the two most abundant 
subclasses of glycosphingolipids. Glycosphingolipids are major component 
of myelin, accounting for 15-20% of the total lipids in the brain (Sastry 
1985). It has been shown that the concentrations of glycosphingolipids in 
white matters and in myelin are, respectively, about 5-fold and 10-fold 
higher than those in grey matters (O'Brien and Sampson 1965). One or more 
monosaccharides can be added to hexolceramides (GluCer or CalCer) 
forming dihexolceramide (Lactoceramide) or more complex 
glycosphingolipids.  
Sulfatides, produced by cerebroside sulfotransferase, are sulfate esters of 
galactocerebrosides at C-3 of the galactopyranoside moiety (Winzeler et al. 
2011). They are primarily found within myelin, accounting for 4-6% of the 
total lipids in brain (Norton and Poduslo 1973). It is reported to be important 
for the maintenance of CNS myelin (Marcus et al. 2006).  
Gangliosides are a group of complex sialic acid-containing 
glycosphingolipids which is substantially concentrated in grey matters. 
Several studies have shown that it might be involved in AD and angiogenesis 
in tumour growth (Yu et al. 2011). 1.2.1.1.4.3 Sphingomyelin 
Upon synthesis on the cytosolic surface of the endoplasmic reticulum 
(ER), ceramide is transferred to Golgi apparatus where the bulk of ceramide 
receives a phosphocholine headgroup from PC to form sphingomyelin. This 
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process is catalyzed by a SM synthase (SMS) (Tafesse, Ternes, and Holthuis 
2006). SM is a major lipid of the myelin membrane. It has been reported that 
during the myelinating period in brain development, the proportion of SM in 
myelin remained unchanged (O'Brien and Sampson 1965) while the fatty 
acid pattern of SM shows significant alteration (Svennerholm and Vanier 
1973). The long acyl chain SM d18:1/18:0 decreased significantly from 82% 
to 33% and the very long acyl chain SM d18:1/24:1 increased significantly 
from 4% to 33% in white matters, suggesting the fatty acid pattern of SM 
plays an essential role in myelination. 
1.2.1.2 Major protein in myelin 
The protein composition of CNS myelin is unique when compared to 
other brain membranes, where the proteolipid protein and basic protein(s) 
making up 60 to 80% of the total protein. 
1.2.1.2.1 Proteolipid protein (PLP) 
PLP is the most abundant protein which accounts for more than half the 
total protein in CNS myelin (Quarles 2005). The full length PLP gene 
encodes a 276 amino acid with a molecular mass of 30 kDa.  PLP is a 
tetraspan protein, with four transmembrane α-helices spanning the myelin 
membrane (Quarles 1999). DM20 is a minor isoform of PLP that arose from 
an alternative splicing of the gene, sharing complete sequence except for a 
35 amino acid segment (Greer and Lees 2002). PLP/DM20 is extremely 
hydrophobic with net basic charge. Its hydrophobic character is further 
increased by the presence of 3 fatty acids, primarily palmitate, oleate or 
stearate in ester linkage to hydroxy amino acids (Quarles 1999).  
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In the CNS, PLP/DM20 is expressed by OLG on polysomes as mature 
protein directly and then transferred to the cell surface where they are 
incorporated into compact myelin (Greer and Lees 2002). Therefore, 
PLP/DM20 is thought to be involved in membrane adhesion and compaction 
of myelin by forming the double-spaced intraperiod line (Greer and Lees 
2002).. It has been reported that mutation of PLP leading to the absence of 
PLP/DM20 in mice could induce hypomyelination due to premature deaths 
of OLG (Quarles 2005). However, PLP/DM20 -null mice can still form 
compact myelin sheaths but subsequently develop axonal swellings and 
degeneration, suggesting dysfunctions in maintenance and survival of axons 
(Griffiths et al. 1998).  
1.2.1.2.2 Myelin basic protein (MBP) 
MBP is a water soluble, positively charged extrinsic membrane protein, 
account for 30% of the total protein in CNS myelin (Quarles 2005). MBP has 
several isoforms ranging from 14 kD to 21.5 kD, arising from different 
transcription start site and also differential splicing of the oligodendrocyte 
lineage gene (golli) (Harauz, Ladizhansky, and Boggs 2009). The isoform of 
18.5 kD is the predominant isoform in human mature myelin and therefore is 
classically considered to be of importance for myelin development and 
stability. It is located on the cytoplasmic leaflets of the OLG corresponding 
to the major dense line in myelin (Quarles 1999). However, increasing 
evidence has demonstrated that MBP is involved in not only membrane 
adhesion, but also in regulating OLG maturation and their myelin forming 
behavior (Hartman et al. 1982; Harauz, Ladizhansky, and Boggs 2009; 
Harauz and Boggs 2013). The absence of, or greatly reduced MBP in mice 
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would cause severe hypomeylination in CNS (Quarles 2005). Although the 
sequence of the MBP gene is highly conserved among mammalians, rodents 
appear to have a more complex system due to the existence of more MBP 
isoforms (Fannon and Moscarello 1991), with 14 kD-MBP being the 
predominant isoform in mature mice and rats. According to Fannon et al., the 
ability to produce the smaller and more cationic 14 kD-MBP may explain the 
rapid and shorter myelination period in rodents (Fannon and Moscarello 
1991). Nevertheless, the variability of MBP in rodents is yet to be elucidated. 
1.2.1.3 Synthesis of myelin components and initiation of myelin 
biogenesis 
Figure 1.5 shows a scheme of the development of OPC to mature OLG 
(Nishiyama et al. 2009). First of all, oligodendrocyte progenitor cells (OPCs), 
characterized by the expression of neuron-glial antigen 2 (NG2) 
and  platelet-derived growth factor alpha (PDGFRα) (but not MBP), begins 
their terminal differentiation and stop expressing NG2 and PDGFRα and 
thus transformed into premyelinating oligodendrocytes (pre-OLGs), 
characterized by the expression of O4 and GalCer (but still not MBP) 
(Nishiyama et al. 2009). This process has been thought to be regulated by 
inhibitory neuronal signals and complex regulators that can switch on myelin 
gene expression (Aggarwal, Yurlova, and Simons 2011).  
The biogenesis of myelin requires major remodelling of the OLG plasma 
in which OLG delivers different components to the growing myelin sheath 
and undergoes cell-surface polarization (Maier, Hoekstra, and Baron 2008). 
In this stage, OLG generates large myelin-membrane sheets which are highly 
asymmetric and similar to compact myelin. It has been reported that MBP 
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contains a high density of positive-charges and can readily interact with the 
negatively charged cellular membrane. MBP’s ability to compact cellular 
membrane is essential for myelin sheath formation while it is problematic for 
the integrity of intracellular membrane such as ER and Golgi apparatus 
(Muller et al. 2013).  Therefore, OLG transform mRNA of MBP instead of 
the protein to cytoplasmic membrane.  MBP is only expressed by 
myelinating OLG. 
 
Figure 1.5 A scheme showing development of OPC to mature OLG 
The two markers for polydendrocytes, NG2 and platelet-derived growth 
factor receptor-alpha (PDGFRα), are expressed by proliferating progenitor 
cells of the oligodendrocyte lineage. As OPCs undergo terminal 
differentiation into mature oligodendrocytes, they lose the expression of 
NG2 and PDGFRα and begin to express the immature oligodendrocyte 
antigen O4, followed by galactoceramide and subsequently myelin basic 
protein (MBP). Only myelinating OLG expresses MBP. Adapted from 
(Nishiyama et al. 2009). 
 
 
1.2.1.4 Membrane structure of myelin 
Myelin is a remarkably stable multilayered membrane structure 
assembled by the cytoplasmic membrane of mature OLG. As mentioned 
above, the basic membrane structure is composed of hydrophobic lipids such 
as glycosphingolipids and phospholipids and highly hydrophobic PLP 
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(Aggarwal, Yurlova, and Simons 2011) (Figure 1.1). Myelin components 
including lipids and proteins are not evenly distributed in the membrane. It 
has been widely accepted that different domains of different composition and 
physical properties can coexist within the bilayer (Gielen et al. 2006). Like 
from every cell type, there are the liquid-ordered membrane microdomains 
known as ‘lipid raft’ and fluid-liquid domains in the plasma membrane of 
OLG. Lipid raft is a cluster of sphingolipids and cholesterol in which 
sphingolipids associate laterally with one another and cholesterol filled the 
voids between the sphingolipids (Simons and Ikonen 1997). The closely-
packed sphingolipid–cholesterol lipid rafts predominantly localized within 
the exoplasmic leaflet. Whereas fluid-liquid domains are consisted of 
phospholipid molecules (Simons and Ikonen 1997).  Lipid rafts in myelin are 
reported to mediate sorting, trafficking and maintaining of the major myelin 
proteins (Maier, Hoekstra, and Baron 2008). It has been suggested that OLG 
produces GalCer and sulfatide prior to synthesizing PLP and MBP when 
they begin terminal differentiation (Aggarwal, Yurlova, and Simons 2011). 
Moreover, rafts provide signaling platforms important for regulation of 
myelin-related processes (Maier, Hoekstra, and Baron 2008). The gel- to 
liquid-crystalline phase transition temperature (Tm) of glycosphingolipids is 
usually very high compared to corresponding PC or SM, and it contributes to 
stabilizing lipid raft domains due to irreversible transitions into stable gel 
phases (Westerlund and Slotte 2009). Interdigitation describes the 
phenomenon whereby membrane may insert the methyl ends of long fatty 
acids from one side across the bilayer mid-plane to protrude amongst the 
acyl chains of the opposite side of the bilayer (Mehlhorn et al. 1988). It 
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normally occurs when the membrane lipids contains two acyl chains with 
significantly different length. Sphingolipids are the most common family of 
lipids with asymmetric acyl chains and therefore, interdigitation is supposed 
to occur in domains rich in sphingolipids (Boggs and Koshy 1994).  
Interdigitation of glycosphingolipids is thought to be one of the possible 
mechanisms of its membrane domains stabilizing function (Westerlund and 
Slotte 2009). 
In compact myelin membrane, the hydrophobic molecules exert a 
repulsive force towards the aqueous cytosol and extracellular fluid. In 
addition to the repulsive forces, hydrogen bonds and Van de Waals 
dispersion forces provide intermolecular attractive forces. Hydrogen bonds 
are formed by the amide and free hydroxyl groups of glycosphingolipid 
located preferentially on the extracellular membrane in the vicinity of the 
lipid–water interface. Van der Waals forces are formed by interactions 
between the methylene groups in acyl chains of adjacent lipids molecules. 
Besides, the highly positively-charged extrinsic MBP interacts with the 
negatively charged lipids and thus brings the two bilayers closer together at 
the cytoplasmic membrane surfaces, forming the major dense line. It is 
believed that the stability of tightly packed myelin membrane is the result of 
a delicate balance between the repulsive forces and the attractive forces 
(Ohler et al. 2004) (Westerlund and Slotte 2009). Disturbance of the balance 
could disrupt normal myelin structure (Bradl 1999). The energy of the 
repulsive and attractive forces is associated with the biophysical properties 
and the composition of myelin lipids and proteins. For example, changes in 
the headgroup area of glycolipids can lead to changes in the curvature and 
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consequently contribute to change of adhesion between the bilayer (Ohler et 
al. 2004). Another example is that long acyl chain (LC) - sphingolipids have 
lower melting temperature than very long acyl chain (VLC) -sphingolipids, 
contributing to high membrane fluidity (Niemela, Hyvonen, and Vattulainen 
2006). Therefore, an appropriate proportion of myelin components might be 
of particular importance in maintaining the myelin structure.   
1.2.1.5 Lipid alteration in SIVD patients 
Recently, the brain lipidomes of non-demented, SIVD and mix dementia 
patients have been analysed by liquid chromatography coupled to tandem 
mass spectrometry, providing relatively comprehensive knowledge of the 
lipid composition and changes of white and grey matters in these brains 
(Lam et al. 2014).  The lipidome of SIVD appeared to be characterized by 
changes mainly in sphingolipids in the white matters including sphingolipid 
fatty acyl chain heterogeneity. There were decreases in Cer, GalCer and 
increases in PS and PG in the overall content.   
1.2.2 Pathophysiology of WML 
1.2.2.1 Non-vascular origins of WML 
1.2.2.1.1 Age-related white matter changes 
Age is almost no doubt a strong risk factor of white matter lesions. WMC 
are regularly found in community elderly with prevalence ranging from 50% 
to 98% (Xiong and Mok 2011).  A population-based MRI Rotterdam Study 
including 1077 subjects aged between 60-90 years reported that only 5% of 
all subjects had no WML in periventricular or subcortical regions and the 
proportion with white matter lesions increased with age(de Leeuw et al. 
2001). In the LADIS Study that enrolled 639 patients aged between 65 and 
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84 years, who, while being investigated for complaints minor neurological 
problems such as mild memory minor cerebrovascular events, age has also 
been reported to be significantly associated with WML(Inzitari et al. 2007). 
A very recent population-based study conducted in Japanese elderly people 
also s revealed that older age are significant predictors of severe 
WML(Yamawaki et al. 2015). 
1.2.2.1.2 Autoimmune inflammation disease  
Multiple sclerosis (MS) is an autoimmune inflammatory disease 
characterized by scattered lesions and demyelination in the white matter 
(Bruck 2005). MS is the most common human demyelinating disease. A 
series of immunopathological events are initiated, amplified and finally 
invaded of CNS parenchyma resulting in damaging of oligodendrocytes, 
myelin sheath and axons(Podbielska et al. 2013). Activated lymphocytes, 
macrophages, microglia can be observed in the white matter from multiple 
sclerosis brains (Bruck 2005). OLG death induced by inflammatory attack 
and recurrent immune attacks is one of the important pathophysiology of 
demyelination in MS (Patel and Balabanov 2012). Besides, inadequate 
remyelination process significantly contribute to lesions that remain largely 
or entirely demyelinated as well(Franklin 2002). 
1.2.2.2 Vascular origins of WML 
Pathologically, WML are characterized by partial loss of myelin, axons, 
and oligodendroglial cell; astrocytic gliosis and microglia activation. WML 
are also seen in small vessel diseases associated with stenosis resulting from 
hyaline fibrosis (Ferrer 2010).  The etiology of WML is yet to be fully 
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understood. But most evidence has suggested that WML is a result of 
incomplete ischemic injury.  
1.2.2.2.1 Vascular risk factors of white matter lesions 
Hypertension is an established risk factor for WML(Xiong and Mok 
2011). Liao et al has shown that hypertension is associated with increased 
odds of WML in the ARIC study which contained a random sample of 1920 
participants aged 55 to 72 years (Liao et al. 1996). In a prospective cohort 
study, duration of hypertension has been found to associate with WML and 
subjects with successfully treated hypertension had only moderately 
increased rates (de Leeuw et al. 2002).  
Other vascular risk factors of white matter lesions include homocycteine 
level (Vermeer et al. 2002; Shimomura et al. 2008; Pavlovic et al. 2011), 
diabetes mellitus (van Harten et al. 2007), atherosclerosis(Manolio et al. 
1999; Pico et al. 2002). However, these risk factors are less consistent since 
several studies reported negative associations (Longstreth et al. 2004; Suwa 
et al. 2015; Falvey et al. 2013). Besides, low vitamin B6 levels are reported 
to be associated with WML in dementia patients(Mulder et al. 2005) since 
adequate vitamin B6 levels are important for the conversion of homocysteine 
into cysteine(Selhub 1999). The inconsistency of these studies may be due to 
that these studies were mostly conducted in patients with all kinds of cerebral 
diseases, diabetes and etc. Therefore it’s difficult to  control confounding 
factors. 
1.2.2.2.2 White matters lesions and ischemia 
Historically, white matters are considered less vulnerable than grey 
matters to ischemic injury induced by a large-artery occlusion (Marcoux et al. 
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1982). However, several research have indicated that ischemia may primarily 
involve white matters capsular infarcts in subcortical areas (Bogousslavsky 
and Regli 1992) and extensive symmetrical necrotic lesions of the central 
white matters with minimal damage to grey matters (Ginsberg, Hedleywhyte, 
and Richardson 1976). Anoxic-ischemic effects due to carbon monoxide 
exposure induced characteristic white matter lesions in both humans and 
animals in the absence of grey matter damage (Pantoni, Garcia, and 
Gutierrez 1996). In addition bilateral common carotid artery (BCCA) 
occlusion in rats have been widely reported to cause mainly white matter 
lesions with little damage to grey matters (Wakita et al. 2002) (Kawaguchi et 
al. 2002) (Ohta et al. 1997). Recently, a mouse model of BCCA stenosis has 
been developed which induces only selective WML without grey matter 
injury (Shibata et al. 2004; Shibata et al. 2007).  
1.2.2.2.3 Oligodendrocyte and ischemia 
OLG and myelinated axons are components of white matters that are 
highly vulnerable to ischemia. Pantoni et al. reported that OLG swelling 
occurred as early as 30 minutes after middle common carotid artery 
occlusion (MCAO) (Pantoni, Garcia, and Gutierrez 1996). Besides, OLG 
showed greater vulnerability than neurons in the cerebral cortex and 
thalamus after transient global ischemia in rat (Petito et al. 1998). OLG is 
rich in microtubules as microtubules are important for transporting myelin 
proteins to their processes. Ischemia can induce a rapid increase of the 
immunoreactivity of the microtubule-associated protein, tau (Dewar and 
Dawson 1995) (Irving et al. 1997) in 40 minutes after the onset of ischemia.  
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In vitro, primary OLGs are less vulnerable than neurons but are more quickly 
injured than other glia cells including astrocytes, microglia, or endothelial 
cells under similar hypoxic conditions such as oxygen glucose deprivation 
(OGD) (Dewar, Underhill, and Goldberg 2003). Additionally, immature 
oligodendrocytes which express O4 have been reported to be more 
vulnerable than mature oligodendrocytes under OGD (Fern and Moller 2000). 
1.2.2.2.4 Blood supply to white matters  
In small vessel disease, stenosis of blood vessels due to thickening of the 
vessel wall and/or accumulation of type IV collagen leads to blood vessel 
occlusion, resulting in a chronic state of hypoperfusion in the region served 
by the occluded vessels. WM receive most of its blood supply through long 
penetrating arteries from the brain surface and anastomoses between the 
penetrating arteries are scarce or absent. As a result, WM is highly 
vulnerable to ischemia when these penetrating vessels are occluded for lack 
of collateral supply (Pantoni 2002) (Ferrer 2010) (Pantoni and Garcia 1997a).  
1.2.2.3 Mechanism of oligodendrocyte injury in ischemic WML 
Development of therapeutic approaches to ischemic WML requires 
improved understanding of the mechanisms for ischemic injury to OLG.  
Several mechanisms including oxidative stress, excitotoxicity, inflammation 
and apoptosis have been shown to initiate oligodendrocyte injury under 
hypoxic–ischemic conditions. 
1.2.2.3.1 Oxidative stress 
In ischemia or hypoxia, oxidative stress occurs when the balance 
between oxidants and antioxidants is disturbed, leading to oxidative cellular 
damage (Valko, Leibfritz et al. 2007). White matters seem to be especially 
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sensitive to oxidative stress due to the high content of lipids, high iron 
content, and decreased antioxidant enzymes in OLGs (Dewar, Underhill, and 
Goldberg 2003). Free radicals can remove a hydrogen atom from a 
methylene group of a fatty acid, leaving the fatty acid carbon with an 
unpaired electron. In aerobic conditions, the carbon radical can react with 
oxygen to produce a peroxyl radical, which is reactive enough to remove 
hydrogen from fatty acid side chains to form a lipid hydroperoxide and 
carbon radical. This process known as lipid peroxidation, once initiated, can 
lead to the formation of many lipid hydroperoxides (Benzie 1996). The 
serum levels of lipid peroxidation markers such as 4-hydroxynonenal (4- and 
malondialdehyde are associated with cognitive deficits in AD and VCI 
patients (Casado, Encarnacion Lopez-Fernandez et al. 2008, Torres, Quaglio 
et al. 2011).  Therefore, lipid peroxidation may play a role in the 
pathogenesis of dementia of the Alzheimer's type (AD) and vascular 
dementia. Miyamoto et al. (Miyamoto, Maki, et al. 2013) has shown an 
increase of reactive oxygen species (ROS) in cerebral WML induced by 
chronic hypoperfusion in mice. In addition, early oligodendrocyte lineage 
cells have been shown to be even more vulnerable to oxidative stress than 
mature OLG in vitro (Dewar, Underhill, and Goldberg 2003).  In addition, 
elevated oxidative stress interfered with OPC differentiation and thus could 
attenuate white matter renewal in vivo (Miyamoto, Maki, et al. 2013).  
1.2.2.3.2 Inflammation 
Inflammatory response in the regions of myelin loss in VCI patients has 
been demonstrated (Rosenberg 2009). Microglia activation and matrix 
metalloproteinase (MMP) elevation have been observed in patients with VaD 
31 
 
(Akiguchi et al. 1997) (Rosenberg, Sullivan, and Esiri 2001) and in 
experimental WML of animals (Farkas et al. 2004; Watanabe et al. 2006). 
Small vessel disease could lead to blood-brain barrier (BBB) damage and 
chronic leakage of fluid and macromolecules in the white matters (Pantoni 
2002). BBB permeability has been found in patients with WML (Xiong and 
Mok 2011) and experimental ischemic WML (Ueno et al. 2002) (Jalal et al. 
2012).  Disruption of BBB can cause the production of several inflammatory 
substances, leading to further white matter injury (Rosenberg 2009). 
 Cytokines including interleukins 1–10, tumor necrosis factor α (TNF-α), and 
interferon γ (INF-γ) can be produced by macrophages and lymphocytes in 
inflammatory tissues (Feghali and Wright 1997). Activation of cytokine 
receptors has been reported to induce oligodendroglial death in adult 
demyelinating disorders (Casaccia-Bonnefil 2000).  
In addition OPC is sensitive to inflammatory injury such as cytokine 
(Baerwald and Popko 1998), which impairs their proliferation or 
differentiation abilities of myelin repair.  
Other inflammatory mediators are also reported to be involved in 
hypoperfusion-induced WML. Liu et al. (Liu et al. 2013) found that C5 
complement protein, a potent inflammatory mediator, deposited in white 
matter of mouse subjected to chronic hypoperfusion and worsen the WML.   
1.2.2.3.3 Apoptosis 
Apoptosis is programmed cell death which is highly regulated (Kerr, 
Wyllie, and Currie 1972). It can be beneficial for helping body to eliminated 
dysfunctional cells or destructive for inducing undesired cell death and tissue 
damage (Thompson 1995). Bcl-2 protein family are well-established key 
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regulators of apoptosis (Czabotar et al. 2014). They can be divided into 
subfamilies of proapoptotic molecules such as Bax and BaK or prosurvival 
molecules such as bcl-2 and Bcl-Xl (Martin and Elkon 2004).  Apoptosis is 
well-known to depend on the cell death execution of cysteine-requiring 
aspartate-directed proteases (caspases) (Kumar 2007). During cerebral 
ischemic injury, apoptosis can occur through two pathways: the intrinsic and 
extrinsic (Unal-Cevik et al. 2004). In intrinsic pathway, cerebral ischemia 
increases cytosolic calcium levels that could induce truncated Bid (tBid). 
tBid interacts with Bak and Bax located to the outer membrane of 
mitochondria, causing mitochondrial membrane rupture and cytochrome c 
releasing (Eskes et al. 2000). Then caspases-9 and subsequently caspases-3 
are activated, which leaves nDNA repair enzyme leading to DNA damage 
and apoptosis (Kumar 2007). In extrinsic pathway, cerebral ischemia induces 
forkhead family of transcription factors and its target genes such as Fas 
ligand (FasL) that triggers recruitment of the Fas-associated death domain 
protein (FADD). FaDD activates cascade of caspases resulting in apoptosis 
(Martin-Villalba et al. 1999).  
A number of studies have reported an increase of apoptotic cells, 
predominantly OLGs, in autopsy brain slices from patients with WMLs 
(Brown et al. 2000; Brown et al. 2002). It has been reported that chronic 
cerebral hypoperfusion induced WMLs in association with up-regulation of 
apoptotic signaling such as TNF-alpha and Bax and DNA fragmentation in 
OLG (Tomimoto et al. 2003). Shibata et el. has reported that inhibition of 
caspases in OLG of a transgenic mouse line that selectively expresses p35, a 
broad-spectrum caspase inhibitor significantly reduced ischemia-induced cell 
33 
 
injury in vivo (Shibata et al. 2000). Besides, glutamate toxicity can 
contribute to the oligodendroglia apoptosis via caspase-3 activation (Ness 
and Wood 2002).  
1.2.2.3.4 Failure in OPC differentiation 
Advances in understanding the mechanism of brain injury and 
neurodegeneration such as excitotoxicity, oxidative stress, and apoptosis 
have provided a number of targets and drugs for neuronal disorders. 
However, almost all clinical trials of neuroprotectants for the treatment of 
acute stroke have failed (Lo 2010). There is an emerging concept that CNS 
pathophysiology is significantly influenced by a balance between initial 
injury and endogenous repair (Lo 2010). For example, ischemic brain injury 
can cause a wide spectrum of neurovascular deleterious responses. At the 
same time many endogenous neuroprotective responses such as 
compensatory neurogenesis, angiogenesis, neuroplasticity and vascular 
remodelling can occur (Miyamoto, Maki, et al. 2013). A central principle of 
regenerative biology is that processes controlling tissue generation during 
development often control its regeneration (Gallo and Deneen 2014). 
Although the most rapid and dramatic myelination in human brain occurs 
between midgestation and the end of the second postnatal year, it continues 
into the third decade in the brain (Kinney et al. 1994).  Several researches 
have indicated that OPC can still generate myelin-forming mature 
oligodendrocytes in the adult cerebral white matters, sustaining the white 
matter homeostasis by endogenous repair and renewal process (Nishiyama 
2007; Levine, Reynolds, and Fawcett 2001).  OPCs react rapidly in response 
to various demyelinating injuries. They can proliferate and migrate to the 
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lesion sites (Polito and Reynolds 2005). OPC number decreases upon onset 
and progression of remyelination concomitant with appearance of BrdU+ 
mature oligodendrocytes  have been reported (Watanabe, Toyama, and 
Nishiyama 2002; Reynolds et al. 2002), suggesting at least a part of OPCs 
differentiation into mature OLG. However, the extent and quality of 
endogenous remyelination is usually suboptimal because multiple factors 
could restrict the multiple remyelination steps including lacking of necessary 
factors that promote oligodendrogenesis, cell death among newly generated 
OLG, inhibitory factors from the post –injury environment that impede 
remyelination and deficient expression of the key growth factors for proper 
re-construction of myelin sheaths (Alizadeh, Dyck, and Karimi-Abdolrezaee 
2015).  Miyamoto et al. (Miyamoto et al. 2010) have shown that chronic 
hypoperfusion causes WML and significant OPC generation. However the 
differentiation of the newly produced OPC has been disrupted in vivo and in 
vitro where chemical hypoxic reagent CoCl2 which act as HIF-1α stabilizer 
can attenuate primary OPC differentiation (Miyamoto et al. 2010). 
Edaravone, a radical scavenger, can rescue OPC differentiation, ameliorate 
myelin loss, and restore working memory function (Miyamoto et al. 2010).  
However, clinical trials of antioxidants in treating VCI are disappointing 
(O'Brien et al. 2003). Therefore, investigations into alternative mechanisms 
and signalling pathways that involved in this hypoxia-induced differentiation 
disruption may be of great importance in understanding and repairing WML 




1.2.3 Animal models of WML 
In order to further understand the pathogenesis, pathology, molecular 
mechanism of WMLs, a number of animal models for white matter damage 
have been developed. In terms of similarity to human WMLs, models using 
those gyrencephalic species such as rabbits, dog, cats and sheep  may appear 
to have some advantages over the rodent models (Hagberg, Peebles, and 
Mallard 2002). However, rodents are more widely available, less expensive 
and more used by researchers than any other species. Here, we focus on the 
rodent models. These models are generally divided into three categories: 
ischemia/hypoperfusion, infection/inflammation and excitotoxicity models. 
1.2.3.1 Ischemia/hypoperfusion models 
In ischemic models, hypoperfusion of focal or global can be induced by 
occlusion or stenosis of the common carotid arteries (Choi et al. 2011) (Jiwa, 
Garrard, and Hainsworth 2010). 
Rat permanent bilateral common carotid artery occlusion or ligation 
(pBCCAO or pBCCAL) (Ni et al. 1994), and mouse bilateral carotid stenosis 
(BCAS) (Shibata et al. 2004) belong to the global hypoperfusion models. 
They can be further divided into chronic or transient models according to 
whether there is reperfusion. Middle cerebral artery occlusion (MCAO) 
(Roof et al. 2001) is a popular focal ischemia model which is widely used in 
stroke studies. It can induce cortical, caudate and subcortical white matter 
lesions. 
In the vessel occlusion models above, white matter lesions are 
consistently reported. Histological examinations show demyelination 
(Pantoni, Garcia, and Gutierrez 1996; Wakita et al. 2002), loss of myelin 
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basic protein (Walker and Rosenberg 2010) and microglial and astrocyte 
activation (Farkas et al. 2004). Cognitive impairment has also been observed 
in these models (Ni et al. 1994) (Ohta et al. 1997) (Shibata et al. 2007). 
Besides the white matter lesions, grey matter lesions and neuronal loss are 
sometimes observed in relatively more severe ischemia models such as 
pBCCAo in rats, tMCAO (Ohtaki et al. 2006) (Pappas et al. 1996). Besides, 
transient MCAO is more suitable to be used as a stroke model since it mainly 
induces large infarcts in cortex instead of diffused WML in subcortical 
region. pBCCAo or pBCCAL in rats can produce a chronic reduction in CBF 
by 50% to 70% (Hainsworth and Markus 2008), which could be too severe 
for mice resulting in low survival rate during the surgery.  
BCAS was first introduced by Shibata et al. (Shibata et al. 2004). A ~30% of 
CBF reduction was induced by two external microcoils with an inner 
diameter of 0.18mm. WM lesions in the corpus callosum, the anterior 
commissure and optic tract occurred after 14 days without any grey matter 
involvement. Therefore BCAS is a suitable vascular WML model in mice 
with its selective injury in white matters (Shibata et al. 2004) and is now 
widely used. 
Except for these vessels occlusion models, stereotaxic vasoconstrictor 
endothelin-1 (ET-1) injection also induces transient focal lesions. Hughes et 
al. (Hughes et al. 2003) reported an acute reduction in local MRI perfusion in 
the injected hemisphere after 1 hour, oligodendrocytes showed enhanced 
Tau-1 staining throughout the lesioned cortical white matters from 6 hours, a 
loss of neurons observed after 24h in grey matters. However, no disruption 
of the BBB was observed. Frost et al. (Frost et al. 2006) have shown after 
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careful control of the amount and time course of ET-1, white matter lesion 
could be confined to a small area, where demyelinated and tissue necrosis 
were observed.  
Cerebral autosomal dominant arteriopathy with subcortical infarct and 
leukoencephalopathy (CADASIL) is a cerebrovascular small-vessel disease 
caused by mutations of the Notch3 gene in chromosome 19 (Joutel et al. 
1996). It is characterized by frequent migraine attacks, recurrent strokes, 
progressive white matter degeneration resulting in early-onset of VCI  and 
progressing into VaD later in life (Ayata 2010) . Notch3 gene is a member of 
a transmembrane receptor family (Drosophila notch homologues 1 to 4) and 
is predominantly expressed by vascular smooth muscle cells (Joutel et al. 
2010). Notch signaling plays a fundamental role in regulating cell fate 
including differentiation, proliferation, and apoptotic programs (Artavanis-
Tsakonas, Rand, and Lake 1999).To date Notch3 knockout mouse models 
and 4 Notch3 mutant mouse models expressing common CADASIL 
mutations have been developed (Ayata 2010). CADASIL Notch3 knockout 
or transgenic mice show progressive white matter damages (Joutel et al.), 
providing insight into the nature of Notch 3 in CADASIL pathologies and in 
smooth muscle degeneration for vascular dysfunction, and the relevance of 
vascular dysfunction for WML (Ayata 2010) non-ischemic WML models. 
1.2.3.2 Infectious/inflammatory models 
Lipopolysaccharide (LPS) is the infectious agent most often used to 
produce white matter damage in developing brains (Juskewitch et al. 2012) 
partly through activation of toll-like receptor 4 on immune cells with 
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initiation of a generalized inflammatory response (Aderem and Ulevitch 
2000). 
1.2.3.3 Excitotoxicity models 
Brain lesion in the white matters can also be induced by excitatory amino 
acid receptor agonist supporting the excitotoxicity hypothesis of WMLs. 
Marret et al. reported that subcortical injection of ibotenate, a glutamatergic 
agonist, could induce injury in white matter (Marret et al. 1995). However, 
excitotoxicity models show little specificity towards inducing white matter 
damages (Nishio et al. 2010). 
Disrupter energy metabolism is one of the major events leading to nerve 
cell damage in neurological abnormalities. Several mitotoxin injection 
models are developed in which white matter lesions had been observed. 
McCracken et al. (McCracken, Dewar, and Hunter 2001) showed systemic 
injection of the mitochondrial inhibitor 3-nitropropionic acid could induce 
white matter lesions including axonal bulbs and swellings within the striatal 
white matter tracts. It is questionable if this type of models shows any 





1.3 Sphingosine-1-phosphate:  A Bioactive Sphingolipid 
Sphingolipids are named after Sphinx, a Greek mythological creature due 
to its mysterious nature. Over more than 100 years later we have obtained 
increasing understanding of other sphingolipids such as ceramides, 
glycosphingolipids and sphingomyelin, while we are now starting to learn 
more about sphingosine-1-phosphate (S1P). It is derived from sphingosine, 
and was originally thought to be only an intermediate in the metabolism of 
sphingolipids, it is now becoming as a prominent lipid regulator mediating 
several important physiological and pathophysiological processes in higher 
organisms such as cell growth and programmed cell death (Spiegel and 
Milstien 2003). 
1.3.1 S1P synthesis and degradation 
Similar to other signaling molecules, the amount of S1P in tissues is low 
in the region of several magnitudes smaller than other sphingolipids. Trace 
signaling molecules interact with high-affinity receptors that are capable of 
sensing their low levels (Hannun and Obeid 2008). Thus S1P levels in cells 
have to be precisely regulated. Sphingosine kinase (SphK) is the enzyme that 
catalyzes the sphingosine phosphorylation to form S1P (Spiegel and Milstien 
2003). S1P can be dephosphorylation reversibly back to sphingosine by 
specific S1P phosphatase SPP. Another degradation pathway is irreversible 
in which a pyridoxal phosphate-dependent S1P lyase (Spl) degrades S1P to 
hexadecenal and phosphoethanolamine (Spiegel and Milstien 2003). This Spl 
degradation breaks down S1P into non-sphingolipid molecules and is the 




1.3.1.1 Sphingosine Kinases 
1.3.1.1.1 Two isoforms of Sphingosine Kinase: SphK1 and SphK2  
Two isoforms of SphK have been identified. In humans, although the 
SphK1 and SphK2 genes are located on different chromosomes, 
chromosome 17 (17q25.2) and 19 (19q13.2) respectively, the two isoforms 
are highly homologous with five conserved domains (C1-C5) (Bryan et al. 
2008). C1-C3 contains the conserved catalytic domain similar to 
diacylglycerol kinase and ceramide kinase. C2 contains the ATP binding 
domain at SGDGX(17-21)K(R) sequence (Pyne et al. 2009). The unique 
sphingosine recognition site lies with C4 domain, which is important for the 
specificity of this kinase. 
Murine SphK1 is a 49kD protein and was cloned earlier (Kohama et al. 
1998) SphK2 was cloned and characterized later from mouse and human 
(Liu, Sugiura, et al. 2000). On the basis of homology to SphK1, SphK2 
shares around 80% sequence similarity with SphK1 but have an added 200 
amino acids at its N-terminus region, which makes it a predicted 68 kD 
protein.  Besides, transmembrane domains are found at the N-terminus 
region of SphK2.   
It has been reported that SphK2 has lower substrate specificity than 
SphK1. The preferred substrates of SphK1 are D-erythro-sphingosine and D-
erythro-dihydrosphingosine whereas SphK2 also phosphorylate 
phytosphingosine, DL-threo-dihydrosphingosine and FTY720, a S1P 
analogue also named as Fingolimod (Liu, Sugiura, et al. 2000). It is a novel 
immunosuppressant in Phase III clinical trials for the treatment of MS and 
for organ transplantation. While, other research has found that SphK2 is the 
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main isoform that phosphorylates FTY720, the efficiency is only at 15% of 
the rate of phosphorylation of its natural substrate sphingosine (Paugh et al. 
2003). Thus, FTY720 is actually a competing SphK2 inhibitor. In addition, 
FTY720 has been reported to inhibit both gene expression and protein level 
of SphK2 in neuroblastoma cell lines (Li, Hla, and Ferrer 2013). Substrates 
specificity difference may suggest that significant differences exist in their 
substrate binding pockets. However, the physiological significance of this 
difference in substrate specificity remains unknown.  
1.3.1.1.2 Localization of SphKs 
Lacking of transmembrane domains or identifiable nuclei localization 
sequences, SphK1 is mainly cytosolic (Kohama et al. 1998). It is 
ubiquitously expressed in adult brain, heart, spleen, lung, kidney, and testis 
but mRNA levels are highest in adult lung and spleen and there were barely 
detectable levels in skeletal muscle and liver (Kohama et al. 1998). SphK2 is 
highly expressed in the brain, kidney, and liver (Liu, Sugiura, et al. 2000). It 
seems that SphK2 is the predominant isoform in the brain, showing higher 
activity and mRNA expression levels in neuronal and glial cells (Blondeau et 
al. 2007). Because of the transmembrane domains and nuclear localization 
signal sequences ((RGRRGGRRR) with an arginine cluster in the N-terminal, 
SphK2 localization is variable and depends on the types of cells (Igarashi et 
al. 2003) (Bryan et al. 2008). For instance, SphK2 is present in the plasma 
membrane, mitochondria, ER, Golgi, and in the cytosol of HEK 293 cells 
(Hait et al. 2006) and it is predominantly localized in the nucleus in COS7, 




1.3.1.1.3 Activation and regulation  
SphK activity is upregulated by both posttranslational and transcriptional 
processes. In addition, both enzymes also possess intrinsic catalytic activity 
in the absence of agonist stimulation (Pitman, Pham, and Pitson 2012). This 
basal SphK activity has been proposed to have a housekeeping role in 
maintaining cellular sphingosine and ceramide levels (Neubauer and Pitson 
2013).  1.3.1.1.3.1 Post-translational activation of SphK1 and SphK2 
A wide range of agonists including various cytokines such as tumor 
necrosis factor-α (TNF-α),  interleukins and hormones and growth factors 
such as platelet-derived growth factor  (PDGF),  epithelial growth factor 
(EGF), vascular endothelial growth factor (VEGF) , platelet-activating factor 
(PAF), nerve growth factor (NGF),  basic fibroblast growth factor (bFGF), 
and lysophosphatidic acid has been demonstrated to active SphK1 through 
post-translational modifications (Bryan et al. 2008 ; Wattenberg, Pitson, and 
Raben 2006). SphK1 activation results from phosphorylation of serine 225. 
SphK1 has a binding site for extracellular-signal regulated kinase (ERK) 1/2 
and both ERK1 and ERK2 phosphorylate SphK1 at Ser225 (Pitson et al. 
2003). However, Wattenberg et al. pointed out that the enzymatic increase by 
1.5 to 3-fold on the catalysis is relatively moderate. Instead the 
phosphorylation-induced translocation of SphK1 is the key to SphK 
signalling function. It seems that both SphK synthesize S1P within 
membrane compartments and thus localization of SphK to membrane is 
needed. Agonist mentioned above induce translocation of SphK1 binding to 
anionic lipids in the plasma membrane, resulting in the activation of SphK1 
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(Wattenberg, Pitson, and Raben 2006) (Hannun and Obeid 2008). Besides, 
several adaptor proteins such as PRK118 (Hayashi et al. 2002), aminoacylase 
1 (Maceyka et al. 2004) and PECAM-1 (Fukuda et al. 2004) have been 
indicated to influence the translocation of SphK1.  
Similar to SphK1, the catalytic activity of SK2 can be rapidly stimulated 
by a number of agonists, including EGF (Hait et al. 2005), TNF-α 
(Mastrandrea, Sessanna, and Laychock 2005), IL-1b (Mastrandrea, Sessanna, 
and Laychock 2005). Like SphK1, SphK2 activation is also regulated by 
phosphorylation via ERK1/2 at Ser351 and Thr578 (Hait et al. 2007).  Little 
is known about the translocation of SphK2. It has a nuclear localization 
signal sequence within its N-terminal region. It has been observed that 
SphK2 can enter the nucleus and cause inhibition of DNA synthesis, 
resulting in cell cycle arrest at G1/S phase (Igarashi et al. 2003). Another 
study has reported that protein kinase D (PKD) could phosphorylate SphK2 
at a putative nuclear export sequence, inducing SphK2 to translocate from 
the nucleus to cytoplasm.  1.3.1.1.3.2 Transcriptional regulation of SphK1 
Little has been known about how SphK expression is regulated. A 55-bp 
fragment containing a activator protein-2 (AP-2) and two specificity protein1  
(SP1) localized ahead of exon 1d has been reported to mediate NGF induced 
rat SphK1 gene transcription (Sobue et al. 2005). Histamine is also found to 
upregulate SphK1 expression via PKC and ERK pathway and AP-2 and SP1 
binding motifs in endothelial cell line EA.hy 926 (Huwiler et al. 2006). In 
addition, hypoxia increases both the activity and expression of SphK1 in 
glioma cells (Anelli et al. 2008). Hypoxia can stabilize hypoxia-inducible 
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factors (HIFs). HIFs bind to hypoxia response elements (HREs) and 
consequently regulate a number of down-stream genes transcriptions. SphK1 
possesses multiple putative HRE sites (Anelli et al. 2008). Schwalm et al. 
(Schwalm et al. 2008) have reported that both HIF-1α and HIF-2α were 
upregulated by hypoxia in endothelial cell line EA.hy 926, inducing SphK1 
gene transcription via binding to the HREs in the promoter region of SphK1. 
There is also some evidence showing that SphK1 may regulate HIF-1α levels 
(Cho et al. 2014) via a S1P/Akt/GSK3β pathway (Ader, Malavaud, and 
Cuvillier 2009; Ader et al. 2015). Thus, it seems possible for a bi-directional 
regulatory mechanism between HIFs and SphK1. It is unclear whether 
SphK2 contains HREs, but hypoxia and HIF-1α have been shown to activate 
the activity and the expression of SphK2 both in vivo and in vitro (Wacker, 
Park, and Gidday 2009; Wacker, Perfater, and Gidday 2012; Yung et al. 
2012; Schnitzer et al. 2009).  
1.3.1.1.4 Inhibitors of SphK 
A number of SK inhibitors have been generated which show potential for 
development as therapeutics for cancer and some other diseases (Pitman and 
Pitson 2010).  1.3.1.1.4.1 Non-specific inhibitors  
N, N-Dimethylsphingosine (DMS) is a naturally occurring N-methylated 
analogue of D-erythro-sphingosine. It is a direct competitive inhibitor for 
purified SphK1 and recombinant SphK1 with a Ki of 8 μM (Pitson et al. 
2000). DMS also inhibits human recombinant SphK2 with a Ki of 12 μM 
non-competitively (Liu, Sugiura, et al. 2000). Nevertheless a study pointed 
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out that purified SphK2 from rat was not inhibited by DMS because of the 
poor affinity of DMS to SphK2 (Vessey et al. 2007).  
N,N,N-Trimethylsphingosine (TMS) is also an analogue of D-erythro-
sphingosine and competitively inhibits purified recombinant human SphK1 
with a Ki of 3.8 µM (Kohama et al. 1998). Inhibition on SphK2 of TMS has 
not been reported.  
A number of earlier studies have reported SphK up-regulations in cancer 
cells and the anti-cancer effects of DMS and TMS by reducing 
chemotherapeutic resistance (Xia et al. 1999) (Jendiroba et al. 2002) (Endo 
et al. 1991). However, DMS and TMS are in fact non-specific inhibitors for 
SphK. Both of these two also inhibits PKC (French et al. 2003). DMS has 
also been reported to inhibit ceramide kinase (Sugiura et al. 2002). Besides, 
DMS enhances the activity of EGF receptor tyrosine kinase (Igarashi et al. 
1989) (Igarashi et al. 1990) and protein kinase A (Ma et al. 2005). Thus 
conclusions on the association of SphK inhibition and anti-cancer effect 
might be compromised due to possible actions on other enzymes. 1.3.1.1.4.2 SKI-II 
SKI-II [2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole], has been 
shown to be a SphK1/Sphk2 dual inhibitor with a slightly higher potency 
towards SphK2 than towards SphK1 with a Ki values of 16.1 and 7.9 L µM 
for SphK1 and SphK2 respectively (Gao et al. 2012). It inhibits SphK 
specifically without inhibiting ERK2, PI3k, and PKC-α up to 60 µM (French 
et al. 2003). X-ray co-crystal structure analyses revealed that SKI-II binds to 
the sphingosine binding site (Gustin et al. 2013), which may explain its 
higher specificity for SphK over other kinases (French et al. 2003). SKI-II 
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inhibited S1P production in breast cancer cell line MDA-MB-231 which 
expresses high levels of SK activity (French et al. 2003) and  in mouse 
mammary adenocarcinoma cells with an IC50 of <1 μM (French et al. 2006). 
Moreover, SKI-II was shown to be orally bioavailable and could be 
measured at therapeutically relevant levels in vivo with a half-life of >8 
hours (French et al. 2006). SKI-II has been shown to inhibit hypoxia-induced 
SphK activation in mice by oral gavage at 100mg/kg (Yung et al. 2012) 
(Kim et al. 2007). Intraperitoneal injection with SKI-II at a dose of 50mg/kg 
could reduce endogenously generated S1P and ameliorate antigen-induced 
bronchial smooth muscle hyperresponsiveness (Chiba et al. 2010). 
Interestingly, a few studies reported that 10µM SKI-II not only inhibits 
SphK1 activity but also reduces the protein expression by enhancing the 
degradation of this enzyme via an ubiquitin-proteasomal pathway and/or 
activation of the proteasome in various cell lines (Loveridge, Tonelli et al. 
2010, Ren, Xin et al. 2010, Cingolani, Casasampere et al. 2014). It is not 
clear whether SKI-II can degrade SphK2 in a similar manner. SKI-II is 
commercially available and is one of the most commonly used SphK 
inhibitors. 1.3.1.1.4.3 Selective SphK1 or SphK2 inhibitors 
Growing evidence has shown that SphK1 and SphK2 have different, 
even opposite functions in many situations (Maceyka et al. 2005). Therefore, 
it is necessary to apply isoform-selective inhibitors to further elucidate their 
roles in regulating cell signalling pathways. 
ABC294640 is a selective SphK2 competitive inhibitor with a Ki of 
7.3µM (Gao et al. 2012). No effect was observed on SphK1, or the closely 
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related diacylglycerol kinase, at concentrations up to 100 µM (French et al. 
2010). It has been reported to inhibit S1P production in human retinal 
endothelial cells (Maines et al. 2008), in rodent models of inflammatory 
disease (Maines et al. 2010) and ischemic injury (Yung et al. 2012) and also 
a variety of other diseases (Neubauer and Pitson 2013). ABC294640 exhibits 
anti-tumour activity in various cancer cells (French et al. 2010) (Beljanski, 
Knaak, and Smith 2010). It also has oral bioavailability in a rat model of 
diabetic retinopathy (Maines et al. 2006). ABC294640 is now in the early-
phase clinical trial for treating solid tumor.  
CB5468139 or SKI-I, is a potent selective SphK1 inhibitor with a Ki of 
0.3 µM which decreased kidney adenocarcinoma A498 proliferation (Gao et 
al. 2012). However, it affect several other signalling proteins including FAK, 
p53, AKT as well (Gao et al. 2012).  
1.3.2 S1P regulating cell fate: an Intracellular Mediator: 
S1P may have dual functions. First, it might act as intracellular regulators 
to regulate survival and growth. Second, it couple S1P receptors in both an 
autocrine and paracrine manner and subsequently activate numerous 
downstream signaling pathways (Spiegel and Milstien 2003). 
Ceramide and sphingosine have generally been associated with cell death 
via apoptosis or growth arrest (Hannun and Obeid 2002). By contrast, S1P 
has been widely reported to enhance growth and cell survival processes in 
diverse cell types (Spiegel and Milstien 2002). Elevated S1P levels promote 
proliferation, accelerate the G1–S transition of the cell cycle, and induced 
DNA synthesis have been shown in in NIH 3T3 fibroblasts and HEK293 
cells (Olivera et al. 1999). Increased intracellular S1P levels could suppress 
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apoptosis induced by serum-withdraw through blocking c-Jun amino 
terminal kinase (JNK) and activation of the caspases cascade (Edsall et al. 
2001).  In addition, S1P have its role in Ras and nuclear factor κB (NF- κB ) 
signalling (Shu et al. 2002; Nava et al. 2002; Xia et al. 2002). Recent studies 
have suggested a pathway in which VEGF stimulated SphK1 via PKC to 
produce S1P, which acted as an intracellular second messenger to mediated 
VEGF-induced activation of Ras and consequently MAPK/ERK signalling 
and cell growth (Shu et al. 2002). 
1.3.3 S1P receptors 
S1P was first reported as the ligand for the orphan G-protein-couple 
receptor (GPCR) endothelial differentiation gene 1 (S1P1, EDG1) receptor. 
Since then, it has been known that another important role of S1P is to act as a 
ligand of the EDG family. By now, five members of the receptors which 
have high affinity for binding with S1P and dihydro-S1P have been 
identified. They are S1P1 (EDG1), S1P2 (EDG5), S1P3 (EDG3), S1P4 
(EDG6), and S1P5 (EDG8). They are ubiquitously expressed and bind to a 
variety of G proteins, which enable S1P to initiate various downstream 
physiological processes such as cytoskeleton rearrangement (Singleton et al. 
2005), cell motility (Rosenfeldt et al. 2001; Sugimoto et al. 2003), 
angiogenesis (Wang et al. 1999) and vascular maturation (Liu, Wada, et al. 
2000). S1P receptors may differentially regulate the Rho family, particularly 
Rho and Rac (Lee et al. 1999).  
1.3.4 S1P receptors in the brain 
The brain has the highest concentration of S1P compared to the other 
tissues in rat (Edsall and Spiegel 1999). S1P receptors are also abundant in 
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both neurons and glia in CNS (Bryan et al. 2008). NGF-induced elevation of 
S1P regulates neurite outgrowth /extension in neurons via S1P1 with Rac 
(Toman et al. 2004).  S1P1 activation has been reported to induce 
depolarization-induced glutamate release in hippocampus neurons (Kajimoto 
et al. 2007), promote neural stem cells and astrocyte motility to site of injury 
(Kimura et al. 2007; Mullershausen et al. 2007), mediate ERK activation in 
C6 glioma and astrocytes (Sato, Ui, and Okajima 2000) (Osinde, 
Mullershausen, and Dev 2007). Whereas, S1P2 is reported to inhibit neurite 
extension in neurons via Rho (Toman et al. 2004), inhibit glioblastoma 
motility (Malchnkhuu et al. 2008) and increase glioma invasion (Young and 
Van Brocklyn 2007). Besides, S1P2 null mice exhibit spontaneous seizures 
(MacLennan et al. 2001), and loss of vestibular function (MacLennan et al. 
2006). S1P3 may inhibit neurite extension in PC12 cells (Toman et al. 2004). 
S1P4 has only been found in lymphatic and hematopoietic tissues (Schulze et 
al. 2011). S1P5 is selectively expressed in oligodendrocytes (Yu et al. 2004), 
suggesting an essential role of S1P5 in oligodendrocyte lineage cells. 
1.3.5 SphK/S1P/S1PR signaling in regulation oligodendroglial lineage 
cells 
S1P receptors are expressed in rat OLG with a relative mRNA abundance 
of S1P5>S1P1=S1P2>S1P3 and S1P1=S1P2=S1P5>S1P3 (Novgorodov et al. 
2007; Yu et al. 2004). On the other hand, human OLGs express the receptor 
mRNA in a relative abundance of S1P5>S1P3>S1P1 (Miron et al. 2008).  
S1P receptors regulate OPC and OLG growth and survival differentially. 
Jung et al. (Jung et al. 2007) indicated that FTY720P, a potent agonist on 
S1P1, S1P3, S1P4 and S1P5 protect rat primary OLG but not OPC from 
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deaths during serum withdrawal through activation of ERK1/2 and Akt. 
Another study by Jaillard et al. (Jaillard et al. 2005) have also reported that 
S1P promoted the survival of mature OLG isolated from adult rat brain 
through activation of S1P5, but not pre-OLG. Although it seemed that S1P 
receptor activation did not protect the survival of pre-OLG or OPC in stress 
conditions, S1P1 has been shown to be involved in the PDGF-induced OPC 
proliferation (Jung et al. 2007). They found that PDGF downregulated S1P5 
and upregulated S1P1 and promoted OPC proliferation, which could be 
abrogated by silencing S1P1. Cui et al. have demonstrated that FTY720P (50 
nM) or S1P treatment without PDGF did not influence the proliferation of 
human OPC. In contrast, both S1P and FTY720P promote the proliferation 
of OPC under PDGF supplemented condition. Jung et al. (Jung et al. 2007) 
also indicated that treatment of low concentration of FTY720P (10nM) for 
72 hours enhanced OPC differentiation while high concentration of 
FTY720P (0.1-1µM) inhibits OPC differentiation. S1P1 specific agonist 
SEW2871 alone had no effect on OPC differentiation (Jung et al. 2007). 
Whereas, Hu et al. (Hu et al. 2011) reported that 10nM FTY720P first 
inhibited OPC maturation as evidenced by the retraction of oligodendrocyte 
processes and then promoted the proliferation but continuously inhibited the 
differentiation during 98 h of treatment. Additionally, S1P5 receptor 
activation has been reported to impede OPC migration (Novgorodov et al. 
2007) and regulate process retraction in pre-oligodendrocytes (Jaillard et al. 
2005) (Miron et al. 2008), both of which may hinder remyelination after 
white matter injury (Keirstead and Blakemore 1999). Overall, the regulatory 
function of the SphK/S1P/S1PR pathway on OLG and OPC survival, 
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proliferation and differentiation appears complex. S1P and S1P receptors 
appear to function differentially in different stages, under different 
conditions and in different cell types and species. All these add to the 
difficulty in elucidating the mechanism of SphK/S1P/S1PR signalling in 
regulating oligodendrocyte lineage cells. 
1.3.6 SphK/S1P/S1PR signaling in hypoxia/ischemia 
As mentioned above, SphK/S1P appears to interact with HIF (Schwalm 
et al. 2008) (Cho et al. 2014), suggesting that SphK/S1P/S1PR pathway may 
have their roles in hypoxic/ischemic injuries. The mRNA transcript 
expression of SphK1 and SphK2 was increased by short-term hypoxia (2 
days), while SphK1 transcript, but not SphK2, was increased under chronic 
hypoxia (14 days) in human pulmonary smooth muscle cells (Ahmad et al. 
2006). Besides, the author also indicated that the increased ability of S1P to 
activate p38 MAPK while under chronic hypoxia improved the ability of 
S1P to stimulate the phosphorylation of ERK1/2(Ahmad et al. 2006). SphK2 
promoter processes transcriptional sites for CREB that can be 
phosphorylated by hypoxia (Pyne et al. 2009). Schnitzer et al. (Schnitzer et 
al. 2009) have shown that hypoxia enhanced SphK2 activity and led to the 
S1P-mediated chemoresistance in A549 lung cancer cells. It is well known 
that solid tumor growth induces tissue hypoxia, which in turn leads to 
induction of VEGF through a HIF1α-dependent mechanism (Ferrara, Gerber, 
and LeCouter 2003). Thus the anti-cancer effect of several SphK inhibitors 
may be due to this mechanism. ABC294640 the selective SphK2 inhibitor is 
now in the early-phase clinical trial for treating solid tumor. Moreover, it has 
also been reported that S1P2 was strongly induced in endothelial cells of the 
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mouse retina during hypoxic stress, resulting in pathological angiogenesis. 
Thus, antagonism of the S1P2 receptors may be a novel therapeutic approach 
of pathologic ocular neovascularization (Skoura et al. 2007).  
Recently, several studies have shown that hypoxic preconditioning 
induced stroke tolerance in mice via SphK2/S1P signaling pathway. It has 
been shown that both activity and expression of SphK2, while not SphK1, 
rapidly increased in the mouse brain during 4h-hypoxic preconditioning 
associated with the stabilization of HIF-1α (Wacker, Park, and Gidday 2009; 
Wacker, Perfater, and Gidday 2012) (Yung et al. 2012). Isoflurane-
preconditioning has also been shown to protect mouse brain against ischemic 
stroke and activate SphK2 in mice (Yung et al. 2012). SphK2 inhibition by 
DMS, SKI-II and ABC294640 abrogated the preconditioning-induced 
tolerance (Wacker, Park, and Gidday 2009) (Wacker, Perfater, and Gidday 
2012) (Yung et al. 2012). In addition, pre-conditioning exhibited no 
protective effect in SphK2-/- mice (Yung et al. 2012; Wacker, Perfater, and 
Gidday 2012). 
1.4 Research rationale and objectives 
WML is one of the most important vascular pathological aspects of VCI. 
However, there are currently no effective measures to ameliorate WML and 
VCI due to lacking of knowledge of the mechanism that how vascular 
diseases induce WML and cognitive impairment. Based on above review, 
WML is characterized with myelin loss and lipid components are essential 
for the stable structure and proper functions of myelin and the high lipid 
content makes white matter extremely vulnerable to ischemia. Although the 
brain lipidome of SIVD patients has been revealed, it is not known if lipid 
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changes can be found in WML induced by chronic hypoperfusion in mouse. 
In addition, WML is associated with loss of OLG and disruption of OPC 
differentiation caused by hypoxia. SphK/S1P/S1PR signaling pathway has 
been reported to interact with hypoxia and regulates OPC and OLG survival, 
proliferation and differentiation profoundly. Yet no evidence has indicated 
the role of SphK/S1P/S1PR pathway in vascular WML. Therefore, the 
objectives of the present study include: 
• Hypothesis 1: Chronic hypoperfusion causes alterations in the 
lipidome of white matters. To investigate the alterations of three 
major myelin lipid classes including cholesterol, sphingolipid and 
phospholipid and the individual sphingolipid molecules in 
hypoperfusion-induced WML 
• Hypothesis 2: Lipid changes are associated with myelin loss and 
white matter lesions. To explain the possible mechanism by 
which lipid changes induce the myelin loss 
• Hypothesis 3: S1P plays an essential role in white matter lesions. 
To investigate S1P and sphingosine levels in WML and the 
activity and expression of SphK in WML induce by 
hypoperfusion in vivo 
• Hypothesis 4: Treatment with a SphK inhibitor, SKI-II, can 
attenuate white matter lesions. To investigate the effect of SphK 
inhibition by SKI-II in WML, the expression of SphK in rat 
primary OLG under chemical-hypoxic condition, and if OPC 




CHAPTER 2 METHOD AND MATERIAL 
2.1 Animal 
All of the animal experimental protocols in this study were approved by 
IACUC (Institutional Animal Care and Use committee) of the National 
University of Singapore. 9- week male C57BL/6 mice and advance pregnant 
Sprague Dawley Rat were obtained from the University Laboratory Animals 
Centre and maintained in the University Animal Holding Unit on a 12 h 
light/dark cycle and they were allowed free access to food and water until the 
mice reach the desirable age (10-12 week) and weight (25~29g) or the rats 
give birth. Careful considerations and efforts have been made to minimize 
the suffering and number of animals.  
 
2.2 Bilateral common carotid artery stenosis model (BCAS)  
10-week-old male C57BL/6 mice (25-29g) were anaesthetized with a 
ketamine/ medetomidine cocktail (100 mg/kg, 10 mg/kg, i.p.), purchased 
from the University Animal Holding Unit. Temperature of mice was 
maintained at 36.5 °C to 37.5 °C with a heating pad throughout the surgery. 
Chronic hypoperfusion was induced by bilateral common carotid artery 
stenosis (BCAS) as previously described (Shibata et al. 2004). After 
anaesthesia, a midline incision (~1.5 cm) was made at the neck of the mouse. 
Then the right common carotid artery (CCA) was carefully isolated from 
surrounding tissues under a surgical microscope (Olympus America). Two 7-
0 silk sutures (B. Braun, Melsungen, Germany) were placed under the right 
CCA around the distal and proximal parts respectively. Then the artery was 
carefully and gently lifted a little by the sutures and placed between the loops 
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of the microcoils as shown in Figure 2.1A (inner diameter 0.18mm, Sawane 
Spring Co, Japan). The microcoil was rotated around the CCA until CCA 
was put in the loops as shown by Figure 2.1B. The distal end of the 
microcoil should be just below the carotid bifurcation (Figure 2.1C). Then 
the 7-0 silk suture was removed gently. Five minutes later, a second 
microcoil was twined around the left CCA with the same procedures.  
 
Figure 2.1 Scheme of BCAS surgery 
A, Microcoil (length 2.5mm, inner diameter 0.18mm). B, CCA narrowed by 
the microcoil, indicated by the green arrow. C, Microcoil was located just 
below the bifurcation. Abbreviations: ICA, internal carotid artery; ECA, 




 Figure 2.2 Relative CBF during the BCAS surgery 
The diagram indicated a representative time course of the hypoperfusion. 
CBF measurement was set at 100% before the microcoils were put in place. 
It can be seen that CBF was reduced to ~60 % of baseline 15-30 min after 
the placement of the two microcoils. 
 
2.3 Cerebral blood flow measurement  
After mice were deeply anesthetized, skin overlying the right skull was 
reflected. A plastic guide cannula (inner diameter 1.5 mm, and length ~4 mm) 
for a laser-Doppler flowmetry probe was temperately glued perpendicularly 
to the skull at 1 mm posterior and 3 mm lateral to the bregma. The cerebral 
blood flow (CBF) was record for 5~10 min for the pre-surgery baseline (set 
as 100%).  The CBF was monitored during the whole process of the BCAS 
surgery and an extra 15 mins after the microcoils implantation. Then the 
probe and guide cannula were removed followed by closing of the incision 
on the head with 4-0 nylon sutures. Atipamezole was injected (i.p.) with the 
dose of 1 mg/ kg (purchased from University Animal Holding Unit) to 
reverse the sedative and analgesic effects of ketamine/medetomidine cocktail. 
Sham-operated animals underwent the same procedures but without the 
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twined the microcoils. The CBF values were expressed as a percentage of the 
baseline value The CBF values were expressed as a percentage of the 
baseline value. A reduction of CBF to ~60% should be observed (Figure 2.2). 
The midline cervical incision was closed with 4-0 nylon sutures (B. Braun, 
Melsungen, Germany).  
2.4 Barnes maze 
Barnes Maze is a dry-land maze test for spatial learning and memory in 
which mice escaped from a brightly exposed circular open platform to a 
small dark chamber. The protocol used in this study is mainly adapted from a 
previous study by Sunyer et al. (Sunyer et al. 2007). 
2.4.1 Equipment and field setup 
2.4.1.1 Animals 
Mice subjected with BCAS or sham-operated 15 days before. Before 
starting each experiment, mice were acclimated to the testing room for 1 h. 
There were 9 mice in each of the two groups in this study. 
2.4.1.2 The maze 
As shown in Figure 2.3A, the maze is in blue color to provide enough 
contrast for computer tracking software between C57BL/6 mice which are 
black and the open surface.  The circular platform has a diameter of 68.5 cm 
with 16 equally distributed holes (6.2 cm diameter; 5 cm between holes) 
along the perimeter and is elevated 105 cm above the floor. In the Barnes 
maze, a small dark recesses chamber is located under one of the holes under 
the platform called a “goal box”. Mice received stimulus would escape from 
the surface to the goal box. All the holes should look the same from the 
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center of the maze so that the mice could not discriminate visually the hole 
with goal box under it from the other holes.  
 
Figure 2.3 Settings for the Barnes Maze 
A, A picture of the blue color platform with diameter of 68.5cm and holes 
with diameter of 6.2cm. B, Location of holes and goal box and the zone 
settings for the video tracking system. Target zone was set so that the 






Bright light and noise were used as reinforcements in this study. The 
light was located right above the center of the platform. A 2000 Hertz pure 
tone of Sine wave generated by an online program on the website: 
http://onlinetonegenerator.com/ played at the maximum volume was used at 
the aversive noise. The same parameters were used during the whole 
experiments. 
2.4.1.4 Room configuration 
Four curtains with different shapes in different colors (triangle, rectangle, 
circle and/or a cross) were hanging surrounding the maze, which would be 
used as the visual cues of the mice. Besides, other furniture in the room such 
as a door, a desk, a shelf could also be the visual cues for the mice. Thus, 
these cues were kept exactly in the same location during the whole 
experiments. The video-tracking system was sensitive to light reflections 
from the platform surface and thus, the dome light of the room was kept to 
the same luminance location during the whole experiments.  
2.4.1.5 Video-tracking system 
A camera was located right above the platform was used record the 
videos. EthoVision XT Version 10.0 (Nolduls Techonology, Netherlands) 
was used to tracking the trace of mice on the platform. Settings were kept the 
same during the whole experiment. Latency, errors and path length can be 
measured and analyzed directly by the tracking system.  
2.4.2 Adaptation period 
The first day of the test is adaptation period. The mouse was placed in 
the middle of the maze covered by a black chamber. 10 s later the mouse was 
60 
 
released from the chamber and the noise was played at the same time. The 
mouse was allowed to explore the platform to find the escape box. If the 
mouse didn’t not find or enter the escape box with 2 min, it would be guide 
to the escape box gently and the noise should be stopped immediately after 
the mouse went into the box. The mouse was allowed to stay in the escape 
box for 30 S. Then the mouse was sent back to its cage and the platform was 
swapped and cleaned with 75% alcohol to eliminate the odor before the next 
mouse was placed onto the maze. There was only one section for adaptation 
period. 
2.4.3 Spatial acquisition phase 
24 h after adaptation period, the acquisition phase began. The mouse was 
placed in the center of the maze covered by black chamber just the same as 
in adaptation period. As soon as the chamber was lifted, the noised and video 
tracking was swift on. The trial ended when the mouse entered the escape 
box or after 5 min it had elapsed. If the mouse didn't enter the escape box, it 
would be guided into it gently and let it stay inside for 30 S. The noise was 
shut down immediately the mouse entered the escape box. After that the 
mouse was sent back to its home cage until the next trial. The platform was 
cleaned with 75% alcohol to avoid olfactory cues. Each mouse received 3 
trials per day with an inter-trial interval of 1 h and there were 3 consecutive 
training days in the acquisition phase.  
2.4.4 Probe trial 
The probe trial was conducted 24 h after the last training day to assess if 
the animal remembered the location of target goal. The escape box was 
removed and the target hole was closed. The mouse was put on the surface 
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and relapsed as it is done in acquisition phase but allowed to explore the 
maze for 2 min with the noise on.  
2.4.5 Data analysis 
2.4.5.1 Acquisition phase 
Primary latency (s) primary path length (cm) and primary errors are 
designated as the time, moving distance and pokes in wrong holes before the 
mouse reached the target hole for the first time. These parameters were 
measured by the tracking software and were averaged in blocks of trials per 
day. Difference between sham and BCAS groups were analyzed by Student’s 
t-test. Primary errors were checked manually because the software might not 
be accurate to detect the head deflections into wrong holes. 
Searching strategy is an important parameter to indicate if the mouse had 
learnt to escape with spatial memory. The search strategies can be defined 
into three categories: direct, serial or mixed. In direct strategy, the mouse 
moved directly to the target hole or to the two holes adjacent to the target 
hole (Hole 1 and Hole 15 as shown in Figure 2.3.B). In serial strategy, the 
mouse first visited wrong holes and then searched at least two adjacent holes 
in serial manner in clockwise or counter-clockwise direction to find the 
target hole. In mixed strategy, the mouse searches holes separated and in 
unorganized manner other than direct or serial strategy. Only direct strategy 
is considered to be the spatial strategy. Searching strategies were determined 
manually with the video records of each trial and analyzed with Fisher’s 
exact test to show the association of the strategy and the surgery types 




2.4.5.2 Probe trial 
In addition to primary latency, primary path length, primary errors and 
searching strategy, total errors during the 2 min and accumulative time 
(Duration) of mouse spent in each of the four zones were measured by the 
tracking software to demonstrate the preference to the target holes. The maze 
platform was divided into five zones as shown in Fig 2.3.B. The differences 
of duration of each zone within the group were compared by paired t-test and 
by student’s t-test between groups.  
 
2.5 SKI-II Treatment  
 (4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol) also named as SKI-
II (Selleckchem) , was dissolved in Dimethyl sulfoxide (DMSO, Sigma) at 
the concentration of 25mg/ml. BCAS mice were divided into three groups:  
BCAS, BCAS-Vehicle and BCAS-SKI-II.  BCAS-SKI-II mice received SKI-
II (50mg/kg, i.p) immediately after the surgery and every other day thereafter 
up to day 15, while the another group received vehicle (DMSO, 50 µl) on the 
same regimen. The rest received nothing. N values of each experimental 
group are listed in the figure legends of the respective experiments.  
 
2.6 Coronal brain slice Preparation 
2.6.1 Reagent 
Chemicals are purchased from Sigma-Aldrich if not stated otherwise. 
2.6.2 Procedure 
Fifteen days after surgery, the mice were anaesthetized with 
ketamine/medetomidine and underwent intra-cardiac perfusion with 0.01M 
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PBS at a rate of 2.5mL / min until the perfusate exiting the right atrium was 
clear, followed by 4% paraformaldehyde in 0.1 M PBS (25 ml). The brains 
were post-fixed in the same paraformaldehyde solution overnight at 4 °C. 
Then brains were dehydrated in 20% sucrose solution at 4 °C overnight 
before proceeding to dehydration with 30% sucrose solution for 1 day. 
Before fast freezed in liquid nitrogen, brains were coated with Tissue-Tek 
Optimal Cutting Temperature compound (Sakura Finetek, Torrance, CA, 
USA) and then placed in the cryostat (Leica Biosystems, Wetzlar, Germany) 
chamber. Coronal sections (12 μm) were cut with a cryostat at -20ºC and 
mounted onto glass slides (Matsunami Glass, Osaka, Japan) and stored at -
80 °C for use.  
 
2.7 White matter tissue isolation 
Fifteen days after surgery, the mice were anaesthetized with 
ketamine/medetomidine and underwent intra-cardiac perfusion with 25 ml of 
0.01M PBS to flush out the blood. Then the skulls were removed and brains 
were quickly taken out and placed ventral side down in a brain tissue matrix 
(on ice). Brains are subsequently sectioned to five 1mm coronal blocks. 
Corpus callosum (CC) and internal capsule (IC) were isolated using sharp 
forceps under a surgical microscope. Each sample then was divided into two 
equal parts and weighted quickly before collecting to microtubes 
(Eppendorf), and then put in lipid nitrogen immediately, and stored at -80 °C 





2.8 Kluver-Barrera staining 
2.8.1 Reagent 
0.1% Luxol Fast Blue solution 1g of Luxol Fast Blue MBS dissolved in 
1000ml 95% ethanol, with 0.5ml glacial 
acetic acid 
0.2% Cresyl Violet solution  2g Cresyl Echt Violet dissolved in 1000ml 
distilled water, 15 drops of 15% glacial 
acetic acid  to every 100ml and filtered just 
before using  
0.05% Lithium Carbonate 
solution 
0.5g Lithium Carbonate( Li2CO3) in 1000ml 
distilled water 
2.8.2 Procedure 
Slide-mounted brain sections prepared as described above were 
immersed in 95% alcohol for 10 to 15 mins for hydration and then were 
transferred to 0.1% Luxol Fast Blue Solution in 56ºC oven overnight (no 
more than 18h). After the sections were cooled down to room temperature, 
excess stain was rinsed off with 95% alcohol followed by washing in 
distilled water. Then the sections were differentiated in 0.05%  Li2CO3 
solution for 30 seconds followed by differentiation in 70% alcohol for 30 
seconds. The two differentiation steps should be repeated until the grey 
matter is clear and white matter is sharply defined under microscope. When 
differentiation is completed, the sections were placed in distilled water 
before counterstain in 0.2% Cresyl Violet Solution for 15 mins. Then 
sections were washed in distilled water and then differentiated in 2 changes 
of 95% alcohol for 5 min each followed by 2 changes of absolute ethanol for 
dehydration and 2 changes of histo-Clear for clearance for 5 mins each 
change. Finally, the sections were mounted with CV Ultra mounting media 
(Leica Biosystem) and dried before microscope checking. 
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2.9 Immunofluorescence staining  
2.9.1 Reagent 
PBS-Tx 0.01 M PBS with 0.1% Triton-X100  
Blocking buffer 5% goat serum in PBS-Tx 
Primary antibody Anti- HIF-1α (GeneTex Inc. U.S) in PBS-
Tx (1:1000) 
Secondary antibody Alexa Fluor® 488, 594 or 647 dye 
( Millipore) in 0.01M PBS (1:200) 
2.9.2 Procedure 
Slide-mounted brain sections were dried at room temperature followed 
by washing with PBS-Tx three times. After that, sections were blocked with 
blocking buffer for 1 h at room temperature to block the unspecific binding. 
Then the sections were incubated with primary antibody overnight at 4°C. 
On the next day, sections were washed with 0.01M PBS 3 times, each time 
for 10 mins and then incubated with secondary antibody at room temperature. 
One hour later, then slides were washed in 0.01M PBS three more times 
followed by nuclei counterstained with DAPI for 3 min. Sections were 
mounted with coverslips via ProLong® Gold Antifade Mountant (Life 
Technologies, USA), waiting for analysis under microscope.  
 
2.10 Microscopy 
The microscope used in this study is the Olympus IX71 microscope with 
QImaging Exi Aqua digital camera (objective lens used included UPLFLN 
10X2PH, NA 0.3; LUCPLFN40X, NA 0.60; UPLFLN 100×OI2 NA 1.3). 





2.11 Western blot analysis 
2.11.1 Reagent 
Lysis buffer RIPA buffer (Cell signaling Technology, 
USA) containing  protease inhibitor 
cocktails (Roche, Germany) and phosStop 
(Roche, Germany) 
1X Running buffer 3.0 g of Tris base, 14.4 g of glycine, and 
1.0 g of SDS dissolved in 1000 ml distilled 
H2O  
1X Transfer buffer 3.0 g of Tris base, 14.4 g of glycine 
dissolved in 800 ml distilled H2O and 200 
ml absolute methanol 
1X PBST 0.01M PBS  with 0.1% Tween-20  
 
2.11.2 Sample preparation 
Isolated white matter tissues were homogenized in cold lysis buffer on 
ice quickly (20µl lysis buffer per 1 mg wet tissue). Homogenized lysates 
were centrifuged for 15 min at 14000 rpm in a precooled centrifuge (4°C). 
The supernatant containing the cytosolic fraction was collected carefully to a 
new microtube. Protein concentrations were determined by Pierce™ BCA 
Protein Assay Kit (ThermoFisher Scientific, USA) with bovine serum 
albumin as standard (Pierce Biotechnology, Rockford, IL, USA) for 
calibration. All samples were adjusted to 20 mg/μl with PBS buffer and then 
diluted with Laemmli buffer (Bio-Rad, Hercules, CA, USA) at a 1:1 ratio 
followed by boiling the mixture at 95-100°C for 5 min.  
2.11.3 Western blot  
Equal amounts of protein (50-150 mg/well according to different target 
protein) were separated by 5-15% sodium dodecyl sulfate-polyacrylamide 
(SDS/PAGE) gel. To be specific, 5% gel was used for NG2, 8% gel was 
used for HIF-1α 15% gel was used for MBP and 10% gel for other target 
protein. Then the protein was transferred onto polyvinylidene difluoride 
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(PVDF) membrane (Bio-Rad, USA) in transfer buffer. After that, the 
membrane was blocked with 10% nonfat dry milk (Bio-Rad, USA) in PBST 
buffer at room temperature for 1 h to prevent unspecific binding. Then the 
membrane was incubated with primary antibodies against MBP (1:2000, Cell 
signaling Technology, USA,), NeuN (1:5000, Cell Signaling Technology, 
Danvers, MA, USA), SphK1 (1:1000, Cell signaling Technology, USA), 
SphK2 (1:1000, Santa Cruz, USA), HIF-1α (1:1000, GeneTex Inc. USA), 
NG2 (1:500, Merck-Millipore, USA), CerS2 (1:5000, Sigma-Aldrich, USA), 
β-actin (1:1000, Cell Signaling Technology, USA) or GAPDH (1:5000, 
Merck-Millipore, USA) at 4 ºC overnight. On the next day, the membranes 
were washed in PBST buffer three times for 10min each time and then 
subjected to incubation with corresponding horseradish peroxidase-
conjugated (HRP) secondary antibodies (1:10000, Merck-Millipore, USA) at 
room temperature for 1 h. Protein bands were visualized by Luminate 
Forte/Crescendo Western HRP Substrates (Millipore Corporation, Billerica, 
MA, USA) and  transilluminator (UVItec Limited, Cambridge, UK). The 
density of the bands was quantified by densitometry analysis using UVIband 
software (UVItec Limited, Cambridge, UK). Protein levels were normalized 
to β-actin or GAPDH.  
 
2.12 Lipid extraction 
2.12.1 Reagent 
Extraction solvent  1:1 butanol : methanol with internal 
standards from Avanti polar lipids 





Internal standards (IS) including PC 14:0/14:0, PE 14:0/14:0, PS 
14:0/14:0, d6 CE (for PC, PE, PS, cholesterol respectively) at a  final 
concentration of 100 ng/ml and IS including Lyso PC 17:0, PG 14:0/14:0, 
C17 Cer,  C8 GluCer (for lysophospholipids, PG, Cer and SM, and glycoCer ) 
at a final concentration of 50 ng/ml were added to ice-cold extraction solvent. 
Then the extraction solvent was added to each white matter tissue (WMT) 
sample isolated before at the ratio of 50 µL per 1 mg wet tissue and then 
WMT were dissected, minced and sonicated at 4°C for 1 h. Sample lysates 
were then centrifuged for 10 min at 14,000 rpm. The total lipid extract 
(supernatant) was collected and aliquot for following analysis. 
 
2.13 Lipid analysis 
2.13.1 Reagent  
All solvents for LC-MS analysis were LC-MS grade and were purchased 
from Fisher Scientific and Merck Millipore if not stated otherwise. 
2.13.2 Phospholipid and sphingolipid 
The samples (1 µl) were injected to liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis with an Agilent system (1200 HILIC-
chip system connected to Agilent 6540 / 6550 Q-TOF and Agilent 6490 
QQQ mass spectrometers). Separation of lipids was carried out using an 
isocratic mobile phase Solvent A and B (tetrahydrofuran: methanol: water in 
the ratio 30:20:50 and 75:20:5 respectively, both containing 10 mM 
ammonium formate) as previously described (Weir et al. 2013). Lipids were 
eluted under gradient conditions (300µl/min) 0% solvent B to 100% solvent 
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B to 8.0 min, 2.5 min at 100% solvent B, then return to 0% solvent B over 
0.5 min then 10.5 min at 0% solvent B before the next injection. Mass 
spectrometer was operated in positive mode for multiple-reaction monitoring 
(MRM). The MRM list of transitions was shown in Table 2.1(sphingolipid) 
and Table 2.2 (phospholipid). 
2.13.3 S1P 
Before injection, the sample was subjected to derivatization as previously 
described (Narayanaswamy, Shinde et al. 2014). Briefly, total lipid extract 
(50 µl) was mixed with internal standard (S1P d18:1 13C2D2, 50 µl, 20 
ng/ml, Toronto Research Chemicals) and TMS-diazomethane (10 µl, 2M in 
hexane, Acros Organics, USA) and incubated for 20 min at room 
temperature under thorough mixing (750 rpm). The derivatization reaction 
was stopped by the addition of acetic acid followed by centrifugation for 10 
min at 14,000 rpm. The supernatants were collected and samples (1 µl) were 
subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analysis with an Agilent system (1200 HILIC-chip system connected to 
Agilent 6540 / 6550 Q-TOF and Agilent 6490 QQQ mass spectrometers) as 
previously described (Narayanaswamy, Shinde et al. 2014). Mobile phase 
Solvent A and B consisted of 50% and 90% acetonitrile in water respectively, 
containing 25 mM ammonium formate pH 4.6. Analytes were separated with 
the following gradient: 100% B from 0 to 1.5 min, 40% B from 1.5 to 8.5 
min, 30% B from 8.5 to 10.5 min, and 0% B from 11.5 to 13.0 min, 100% B 
from 13.1 to 19 min. Mass spectrometer was operated in positive mode for 





Cholesterol were analysed using an Agilent HPLC 1100 system with 
Zorbax Eclipse XDB-C18 column (Agilent) coupled with an Applied 
Biosystems 3200 QTrap mass spectrometer (Applied Biosystems, Foster 
City, CA) as previously described (Shui et al. 2011)Briefly, chloroform: 
methanol in ration of 1:1 as the mobile phase at a flow rate of 0.5 ml/min 
was used to elute the analytes. The monitored MRM transitions for internal 
standard were 375.4/161.0 and 369.4/161.0 for cholesterol. 
2.13.5 Lipidomics data processing 
Data were extracted with Analyst Software (Applied Biosystems, Foster 
City, CA, USA). The amounts of lipid classes and individual species were 
normalized by the incorporated internal standard concentration, and then 
normalized to total protein concentration of their correspondent half part of 
WML used for western blot analysis. Mass fraction or molar fraction was 
obtained by normalization of the total amounts of lipids for further analysis.  
 
2.14 Primary oligodendroglia lineage cell culture 
The procedures were adapted from previous studies (Chen et al. 2007; 
Miyamoto, Maki, et al. 2013). 
2.14.1 Reagent 
DMEM20S  DMEM/F12 (Gibco, USA)  with 20% FBS (Biowest, 
USA), 1% penicillin / streptomycin (Gibco, USA)  1mM 
sodium pyrumate 
OPC medium Neurobasal (Gibco, USA) supplied with GlutaMAX 
(Gibco, USA) , 10 ng / mL PDGF, 10 ng/ml FGF (both 
from Peprotech, USA), 1% penicillin / streptomycin, and 
2% B27 (Gibco, USA) 
OLG medium DMEM supplied with GlutaMAX, 1% penicillin / 




2.14.2 Equipment setup 
75 cm2 flasks were coated with filtered 0.01% poly-D-lysine (Sigma-
Aldrich, USA) for 1-2 h in in 37 °C incubator or overnight at room 
temperature. Then the coating solution was removed and the flask was 
washed three times with sterile distilled H2O and dried completely in a tissue 
culture hood.  
48-well plates, Petri dishes and round coverslips placed in 24-well plates 
were coated with filtered 0.005% poly-D-ornithine (Sigma-Aldrich, USA) 
for 1-2 h in in 37 °C incubator or overnight at room temperature. Then the 
coating solution was removed and the flask was washed three times with 
sterile distilled H2O and dried completely in a tissue culture hood. 
Microdissecting scissors and forceps should be autoclaved in advance. 
And all the procedures should be done in a biosafety cabinet (BSC). 
2.14.3 Dissection and plating and culture of neonatal rat cortices 
Two P1–2 rat pups were anaesthetized by burying them in ice for 1-5 
min and soaked in 70% alcohol for sterilization. The skin was cut open along 
the midline of the head from the base of the skull towards the mid-eye area 
using microdissecting scissors followed by cutting and removing the skull 
with a curved forceps. Then the cortices were separated and transferred to a 
60 mm Petri dish placed on ice containing 5ml ice-cold  HBSS using another 
forceps (Gibco, USA). It’s important to use different scissors or forceps to 
remove skin, skull and the brain cortices respectively to avoid contamination. 
Remaining heads were subject to the same procedures. The meninges were 
gently peeled off from the cortices and then the cortices were transferred to a 
fresh 60 mm Petri dish placed on ice containing 5ml ice-cold HBSS added 
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with 0.5ml 10x trypsion (Biowest,USA) and 0.001% DNase I.  After cutting 
the cortices into ~1 mm3 chunks with a microdissecting scissors, the tissue 
was incubated in the tissue culture incubator at 37 °C for 10-15 min. Then 
the digested contents were transferred into a 50 ml sterile centrifuge tube. 
5ml DMEM 20S was added to the sterile centrifuge tube to stop the digestion 
and then cells were collected by centrifugation at 100g (~800 rpm) for 5 min. 
The supernatant was aspirated carefully and discarded. Then 10ml DMEM 
was added to the tube for trituration and dissociation with pipette until 
homogenous. Then the homogenous suspension was passed through a 40 µm 
cell strainer placed on a 50 ml conical tube and transferred into one coated 
T75 flask. The flask was incubated at 37°C and 5% CO2 for 8-10 days. The 
DMEM20S medium was changed every three days. 
2.14.4 OPC isolation and culture 
When the mixed glial cells were confluent, the flasks were shaken on an 
orbital shaker (220 rpm) for 1 h to remove the microglia, and then changed 
to new medium followed by 18~20 h shaking. The medium was collected 
and plated on uncoated 10 mm petri-dish for 1 h at 37°C to allow 
contaminating astrocytes and microglia attach firmly to the surface. Non-
adherent cells were then centrifuged and re-suspended in OPC medium and 
then plated onto poly-D-ornithine-coated plates or 60mm petri dish (Day 0). 
The OPC medium was half changed every two days. Cells would be ready 
for use on Days 4-5. To differentiate the OPCs from OLGs, the medium was 




2.14.5 Chemical induction of hypoxia in vitro 
CoCl2 (up to 50 µM) was added to the media of cultured OPCs at Day 4-
5 in order to chemically induce HIF-1α and mimic chronic hypoxia (Piret et 
al. 2002) with or without co-treatment with SKI-II (25 µM, dissolved in 
DMSO) or FTY720 (10nM or100nM, dissolved in DMSO). After treatment 
of 72 h, cell viability was assessed by MTT assays following standard 
protocols. Cells grown on round coverslips were subjected to 
immunofluorescence staining. Briefly, the coverslips with cells grown onto it 
were washed with ice-cold PBS, fixed with 4% paraformaldehyde for 15 min 
then washed three times with PBS-Triton X-100 (0.1%), followed by 
blocking in 3% bovine serum albumin in PBS for 1 h. Then the cells were 
then incubated with primary antibodies against MBP (1:200, GeneTex, USA), 
NG2 (1:200, Merck-Millipore, USA) or HIF-1α (1:100, GeneTex, USA) at 
4°C overnight, washed with PBS three times, and incubated with 
fluorochrome (Alexa Fluor® 488 or Alexa Fluor® 594)-conjugated 
secondary antibodies. Before mounting the coverslips on to glass slides, 
nuclei were counterstained with DAPI, then viewed under an Olympus IX71 
microscope with QImaging Exi Aqua digital camera (objective lens used 
included UPLFLN 10X2PH, NA 0.3; LUCPLFN40X, NA 0.60; UPLFLN 
100×OI2 NA 1.3). All images were acquired by Image-Pro Insight (version 
8.0) at room temperature.   
Cells in petri dish were collected for western blot analysis. Having 
aspirated the medium, cells were washed with ice-cold PBS and harvested in 
200µl RIPA buffer (as described above for white matter tissue) per 60mm 
petri dish. Cell lysates were briefly sonicated for 10 seconds followed with 
74 
 
centrifugation at 14000 rpm for 15 min at 4 °C. The supernatant was 
collected and further processes as described above for white matter tissues. 
Processed samples were subjected to western blot analysis with 10% 
SDS/PAGE gel and incubated with anti-SphK2 (Santa Cruz, USA) and β-
actin (Cell signaling, USA) antibodies and secondary antibodies. 
2.15 Quantification of immunofluorescence staining  
Images of six randomly-chosen views under 40X objective lens were 
acquired for one biological sample. The intensity of HIF-1α of each cell in 
the six images was measured by Image J software and expressed as grey 
scale value in which black was 0 and pure white due to over expose was 255. 
The intensity of HIF-1α for this sample was the average value of all cells in 
the six images. Total three samples for each experimental group were 
measured. 
Similar to HIF-1α, the data used for calculation of OLG (MBP-positive) 
to OPC (NG2 positive) ratio were collected from the same view-chosen 
method from five samples for each experimental group. 
 
2.16 Statistical analysis 
All statistical analyses of the data were performed by SPSS 19 (IBM, 
Armonk, NY). Differences between two groups were compared with 
Student’s t-test. Differences among three or more groups were analyzed by 
one-way ANOVA with post-hoc comparisons of Bonferroni test. Two-way 
ANOVA with repeated measurements post-hoc comparisons of Bonferroni 
test was used as well in Barnes maze experiments. Besides, Fisher’s exact 
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test was performed for analyzing the association between searching strategy 
and groups in Barnes maze. Values are expresses as Mean ± SEM. 
 
Table 2.1 MRM List of Sphingolipids 
Name Transition   Name Transition 
Cer d16:1/C22:0 594.7 -> 236.4 
 
SM 30:1 (IS) 647.5 -> 184.1 
Cer d18:0/C22:0 624.7 -> 266.4 
 
SM 31:1 661.5 -> 184.1 
Cer d18:0/C24:0 652.7 -> 266.4 
 
SM 32:0 677.6 -> 184.1 
Cer d18:0/C24:1 650.7 -> 266.4 
 
SM 32:1 675.5 -> 184.1 
Cer d18:1/C16:0 538.5 -> 264.3 
 
SM 32:2 673.5 -> 184.1 
Cer d18:1/C17:0 (IS) 552.5 -> 264.3 
 
SM 33:1 689.6 -> 184.1 
Cer d18:1/C18:0 566.6 -> 264.3 
 
SM 34:0 705.6 -> 184.1 
Cer d18:1/C20:0 594.6 -> 264.3 
 
SM 34:1 703.6 -> 184.1 
Cer d18:1/C22:0 622.6 -> 264.3 
 
SM 34:2 701.6 -> 184.1 
Cer d18:1/C24:0 650.6 -> 264.3 
 
SM 34:3 699.5 -> 184.1 
Cer d18:1/C24:1 648.6 -> 264.3 
 
SM 35:1 717.6 -> 184.1 
Cer d18:1/C26:1 678.7 -> 264.4 
 
SM 35:2 715.6 -> 184.1 
Cer d18:2/C16:0 536.7 -> 262.4 
 
SM 36:1 731.6 -> 184.1 
Cer d18:2/C22:0 620.7 -> 262.4 
 
SM 36:2 729.6 -> 184.1 
Cer d18:2/C24:1 646.7 -> 262.4 
 
SM 36:3 727.6 -> 184.1 
DHC 16:0 862.6 -> 264.3 
 
SM 37:2 743.5 -> 184.1 
DHC 18:0 890.7 -> 264.3 
 
SM 38:1 759.6 -> 184.1 
DHC 20:0 918.7 -> 264.3 
 
SM 38:2 757.6 -> 184.1 
DHC 22:0 946.7 -> 264.3 
 
SM 39:1 773.7 -> 184.1 
DHC 24:0 974.8 -> 264.3 
 
SM 41:1 801.7 -> 184.1 
DHC 24:1 972.7 -> 264.3 
 
SM 41:2 799.7 -> 184.1 
dhCer 18:0 568.6 -> 550.6 
 
SM 42:1 816.7 -> 184.1 
dhCer 22:0 624.6 -> 606.6 
 
Sphd16:1 272.2 -> 254.2 
dhCer 24:0 652.7 -> 284.3 
 
Sphd18:0 302.3 -> 284.2 
dhCer 24:1 650.6 -> 632.6 
 
Sphd18:1 300.3 -> 282.2 
MHC 16:0 700.6 -> 264.3 
 
Sphd18:2 298.3 -> 280.2 
MHC 18:0 728.6 -> 264.3 
 
GluCer d18:1/8:0 STD 588.8 -> 264.3 
MHC 20:0 756.6 -> 264.3 
  
  
MHC 22:0 784.7 -> 264.3 
  
  
MHC 24:0 812.7 -> 264.3 
  
  





Table 2.2 MRM List of Phospholipids 
Name Transition  Name Transition 
LPC 14:0 468.3 -> 184.1  oddPC 39:6 820.6 -> 184.1 
LPC 15:0 482.3 -> 184.1  oddPC 39:7 818.6 -> 184.1 
LPC 16:0 496.3 -> 184.1  PC 14:0 14:0 (IS) 678.5 -> 184.1 
LPC 16:1 494.3 -> 184.1  PC 30:0 706.5 -> 184.1 
LPC 17:0 (IS) 510.4 -> 184.1  PC 32:0 734.6 -> 184.1 
LPC 17:1 508.4 -> 184.1  PC 32:1 732.6 -> 184.1 
LPC 18:0 524.4 -> 184.1  PC 32:2 730.5 -> 184.1 
LPC 18:1 522.4 -> 184.1  PC 32:3 728.5 -> 184.1 
LPC 18:2 520.3 -> 184.1  PC 34:0 762.6 -> 184.1 
LPC 18:3 518.3 -> 184.1  PC 34:1 760.6 -> 184.1 
LPC 20:1 550.4 -> 184.1  PC 34:2 758.6 -> 184.1 
LPC 20:2 548.4 -> 184.1  PC 34:2 + 2O 790.6 -> 184.1 
LPC 20:3 546.4 -> 184.1  PC 34:2 + O 774.6 -> 184.1 
LPC 20:4 544.3 -> 184.1  PC(O-34:3) +2O 774.6 -> 184.1 
LPC 22:0 580.4 -> 184.1  PC(P-34:2) +2O 774.6 -> 184.1 
LPC 22:1 578.4 -> 184.1  PC 34:3 756.6 -> 184.1 
LPC 22:5 570.4 -> 184.1  PC 34:4 754.5 -> 184.1 
LPC 22:6 568.3 -> 184.1  PC 36:0 790.6 -> 184.1 
LPC 24:0 608.5 -> 184.1  PC 36:1 788.6 -> 184.1 
LPC 26:0 636.5 -> 184.1  PC 36:2 786.6 -> 184.1 
oddPC 29:0 692.5 -> 184.1  PC 36:3 784.6 -> 184.1 
oddPC 31:0 720.6 -> 184.1  PC 36:4 782.6 -> 184.1 
oddPC 31:1 718.5 -> 184.1  PC 36:5 780.6 -> 184.1 
oddPC 33:0 748.6 -> 184.1  PC 36:6 778.5 -> 184.1 
oddPC 33:1 746.6 -> 184.1  PC 38:2 814.6 -> 184.1 
oddPC 35:0 776.6 -> 184.1  PC 38:3 812.6 -> 184.1 
oddPC 35:1 774.6 -> 184.1  PC 38:4 810.6 -> 184.1 
oddPC 35:2 772.6 -> 184.1  PC 38:5 808.6 -> 184.1 
oddPC 35:3 770.6 -> 184.1  PC(P-34:2) 742.5 -> 184.1 
oddPC 35:4 768.6 -> 184.1  PC(P-34:3) 740.6 -> 184.1 
oddPC 35:5 766.5 -> 184.1  PC(P-36:4) 766.6 -> 184.1 
oddPC 37:4 796.6 -> 184.1  PC(P-36:5) 764.6 -> 184.1 
oddPC 37:5 794.6 -> 184.1  PC(P-38:4) 794.6 -> 184.1 
oddPC 37:6 792.6 -> 184.1  PC(P-38:5) 792.6 -> 184.1 
oddPC 39:5 822.6 -> 184.1  PC(P-38:6) 790.6 -> 184.1 
oddPC 39:6 820.6 -> 184.1  PC(P-40:5) 822.6 -> 184.1 
PC(P-40:6) 818.6 -> 184.1  PE 35:2 730.5 -> 589.5 
PC 38:7 804.6 -> 184.1  PE 36:0 748.6 -> 607.6 
PC 40:4 838.6 -> 184.1  PE 36:1 746.6 -> 605.6 
PC 40:5 836.6 -> 184.1  PE 36:2 744.6 -> 603.5 
PC 40:6 834.6 -> 184.1  PE 36:3 742.5 -> 601.5 
PC 40:7 832.6 -> 184.1  PE 36:4 740.5 -> 599.5 
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PC 40:8 830.6 -> 184.1  PE 36:5 738.5 -> 597.5 
PC(16:0/22:6) 806.6 -> 184.1  PE 38:3 770.6 -> 629.6 
PC(18:2/20:4) 806.6 -> 184.1  PE 38:4 768.6 -> 627.5 
PC(O-16:0/0:0) 482.4 -> 104.1  PE 38:5 766.5 -> 625.5 
PC(O-18:0/0:0) 510.4 -> 104.1  PE 38:6 764.5 -> 623.5 
PC(O-18:1/0:0) 508.4 -> 104.1  PE 40:4 796.6 -> 655.6 
PC(O-20:0/0:0) 538.4 -> 104.1  PE 40:5 794.6 -> 653.6 
PC(O-20:1/0:0) 536.4 -> 104.1  PE 40:6 792.6 -> 651.5 
PC(O-22:0/0:0) 566.5 -> 104.1  PE 40:7 790.5 -> 649.5 
PC(O-32:0) 720.6 -> 184.1  PE(14:0/0:0) (IS) 426.3 -> 285.2 
PC(O-32:1) 718.5 -> 184.1  PE(16:0/0:0) 454.3 -> 313.3 
PC(O-32:2) 716.6 -> 184.1  PE(18:0/0:0) 482.3 -> 341.3 
PC(O-34:1) 746.6 -> 184.1  PE(18:1/0:0) 480.3 -> 339.3 
PC(O-34:4) 740.6 -> 184.1  PE(18:2/0:0) 478.3 -> 337.3 
PC(O-36:2) 772.6 -> 184.1  PE(20:4/0:0) 502.3 -> 361.3 
PC(O-36:4) 768.6 -> 184.1  PE(22:6/0:0) 526.3 -> 385.3 
PC(O-38:4) 796.6 -> 184.1  PE(O-18:0/22:5) 780.6 -> 639.6 
PC(O-38:5) 794.6 -> 184.1  PE(P-20:0/20:4) 780.6 -> 639.6 
PC(O-40:6) 820.6 -> 184.1  PC(O-22:1/0:0) 564.4 -> 104.1 
PC(O-40:7) 818.6 -> 184.1  PC(O-24:0/0:0) 594.5 -> 104.1 
PC(P-30:0) 690.4 -> 184.1  PC(O-24:2/0:0) 590.5 -> 104.1 
PC(P-32:0) 718.5 -> 184.1  PE(O-18:1/18:2) 728.6 -> 587.5 
PC(P-32:1) 716.6 -> 184.1  PE(P-18:0/18:2) 728.6 -> 587.5 
PC(P-34:1) 744.6 -> 184.1  PE(O-18:1/20:3) 754.6 -> 613.6 
PE 14:0/14:0 (IS) 636.5 -> 495.5  PE(O-18:2/18:2) 726.5 -> 585.5 
PE 32:0 692.5 -> 551.5  PE(P-18:0/20:4) 752.6 -> 611.5 
PE 32:1 690.5 -> 549.5  PE(O-18:2/20:3) 752.6 -> 611.5 
PE 34:1 718.5 -> 577.5  PE(O-18:2/22:5) 776.6 -> 635.5 
PE 34:2 716.5 -> 575.5  PE(P-18:0/22:6) 776.6 -> 635.5 
PE 34:3 714.5 -> 573.5  PE(O-34:1) 704.6 -> 563.5 
PE 35:1 732.6 -> 591.5  PE(O-34:2) 702.5 -> 561.5 
PE(P-16:0/18:1) 702.5 -> 561.5  PI 38:3 906.6 -> 629.6 
PE(O-36:2) 730.5 -> 589.5  PI 38:4 904.6 -> 627.6 
PE(O-36:5) 724.5 -> 583.5  PI 38:5 902.6 -> 625.6 
PE(P-16:0/20:4) 724.5 -> 583.5  PI 38:6 900.6 -> 623.6 
PE(O-36:6) 722.5 -> 581.5  PI 40:4 932.6 -> 655.6 
PE(P-18:0/22:5) 778.5 -> 637.5  PI 40:5 930.6 -> 653.6 
PE(O-40:6) 778.5 -> 637.5  PI 40:6 928.6 -> 651.6 
PE(P-16:0/18:1) FA 702.5 -> 339.3  PS 14:0 14:0 (IS) 680.5 -> 495.5 
PE(P-16:0/18:2) 700.5 -> 559.5  PS 17:0 17:0 (IS) 764.5 -> 579.5 
PE(P-16:0/18:2) FA 700.5 -> 337.3  PS 36:1 790.6 -> 605.6 
PE(P-16:0/20:4) FA 724.5 -> 361.3  PS 36:2 788.5 -> 603.5 
PE(P-16:0/22:5) 750.5 -> 609.6  PS 38:3 814.6 -> 629.6 
PE(P-16:0/22:5) FA 750.5 -> 387.3  PS 38:4 812.5 -> 627.5 
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PE(P-16:0/22:6) 748.5 -> 607.5  PS 38:5 810.5 -> 625.5 
PE(P-16:0/22:6) FA 748.5 -> 385.3  PS 40:5 838.6 -> 653.6 
PE(P-18:0/18:1) 730.5 -> 589.5  PS 40:6 836.5 -> 651.5 
PE(P-18:0/18:1) FA 730.5 -> 339.3    
PE(P-18:0/18:2) FA 728.6 -> 337.3    
PE(P-18:0/20:4) FA 752.6 -> 361.3    
PE(P-18:0/22:5) FA 778.5 -> 387.3    
PE(P-18:0/22:6) FA 776.6 -> 385.3    
PE(P-20:0/20:4) FA 780.6 -> 361.3    
PG 14:0 14:0 (IS) 684.6 -> 495.5    
PG 16:0 18:1 766.6 -> 577.5    
PG 17:0 17:0 (IS) 768.6 -> 579.5    
PG 18:0 18:1 794.6 -> 605.6    
PG 18:1 18:1 792.6 -> 603.5    
PI (20:4/0:0) 638.3 -> 361.3    
PI 32:0 828.6 -> 551.6    
PI 32:1 826.5 -> 549.5    
PI 34:0 856.6 -> 579.6    
PI 34:1 854.6 -> 577.6    
PI 36:1 882.6 -> 605.6    
PI 36:2 880.6 -> 603.6    
PI 36:3 878.6 -> 601.6    
PI 36:4 876.6 -> 599.6    





Table 2.3 MRM List of S1P 
Name Transition 
13C2D2_S1P(IS) 440.3 -> 60.1 
S1P (d18:0) 438.3 -> 60.1 
S1P (d18:1) 436.3 -> 60.1 
S1P (d18:2) 434.3 -> 60.1 






CHAPTER 3 THE LIPIDOME OF WHITE 
MATTER LESIONS IN MOUSE BRAIN INDUCED 
BY GLOBAL CHRONIC HYPOPERFUSION 
3.1 Introduction 
Dementia and cognitive impairment have become increasingly prominent 
healthcare issues in the aged population. Cerebrovascular diseases are now 
recognized as a major contributor of cognitive impairment (Kalaria et al. 
2008). In particular, white matter lesions (WML), characterized by loss of 
oligodendrocytes, myelin rarefaction and axonal damage are frequently 
observed in patients with vascular cognitive impairment (Ferrer 2010; 
Gorelick et al. 2011).  White matter lesions are believed to contribute to the 
rapid decline of global function in elderly patients (Inzitari et al. 2007). 
Furthermore, research in animal models have shown that WML induced by 
hypoperfusion can cause working memory deficits (Shibata et al. 2007), and 
treatments which ameliorated WML also restored working memory function 
(Miyamoto, Maki, et al. 2013; Dong et al. 2011; Washida et al. 2010).   
Oligodendrocytes (OLGs) form sail-like extensions of their cytoplasmic 
membrane, which wrap around the axon up to 150 layers thick to form the 
myelin sheaths. Myelin is the essential constituent of white matter in the 
CNS, making up 40–50% of the dry weight (Baumann and Pham-Dinh 2001) 
and gives white colour of WM in CNS. Due to the multiple membrane layers, 
myelin contains around 80% lipid content, consisting of mainly three classes 
including cholesterols, phospholipids and sphingolipids (O'Brien and 
Sampson 1965). These lipids act as structural lipids that form the matrix of 
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cellular membranes(van Meer, Voelker, and Feigenson 2008), providing 
barrier function, fluidity characteristics that are essential for cell division, 
reproduction, membrane vesicle trafficking, and raft supporting membrane 
proteins. Moreover, several lipids such as ceramides, S1P have been found to 
act as first of second messengers that regulate various cell signalling 
pathways (Spiegel and Milstien 2003). Myelin loss which is usually 
demonstrated with Kluver-Barrera staining(Kluver and Barrera 1953), a 
method in which luxol fast blue stains for myelin with Nissl counterstain, is 
one of the most prominent characteristics of WML. However, little is known 
about the alterations of lipids in the WML induced by hypoperfusion. 
Besides, thousands of chemically distinct lipid species derived from various 
combinations of backbone structures containing fatty acids markedly 
increase the degree of difficulty in studying these lipids. Lipidomics, as an 
emerging field of analysis of lipids at the systems-level, is based on LC-
MS/MS and provides detailed analysis and global characterization of the 
structure and function of lipids in a living system (Harkewicz and Dennis 
2011). In fact, lipidomics has uncovered lipid aberrations in a variety of 
diseases. For example, Lam et al. (Lam et al. 2014) reported aberrations of 
sphingolipids and phospholipids in the postmortem brain tissues from 
patients suffered subcortical ischemic vascular dementia.      
Global hypoperfusion through vessel occlusion or stenosis is widely used 
for experimental vascular dementia models. Bilateral common carotid 
stenosis (BCAS) in C57BL/6 mice has been described to produce a 
prolonged global cerebral blood flow reduction by ~20-30% by narrowing 
the bilateral common carotid arteries (CCAs) with microcoils, causing 
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selective WML without apparently histological abnormalities in the grey 
matter (Shibata et al. 2004) in 2 weeks after the BCAS surgery.   
In this section, the pathological characteristics of WML and cognitive 
deficits induced by chronic cerebral hypoperfusion in mice are described. 
More importantly, a total of 200 distinct lipid species covering the most 
abundant ones from 13 lipid subclasses, including neutral lipids such as free 
cholesterols; sphingolipids subclasses of ceramide (Cer), glycosphingolipid, 
sphingomyelin(SM); phospholipid including lysophosphatidylcholine (LPC), 
phosphatidylcholine (PC), lysophosphatidylethanolamine (LPE), 
phosphatidylethanolamine (PE),  phosphatidylserine (PS), 
phosphatidyglycerol (PG), and phosphatidylinositol (PI)  in cerebral WMT 




3.2.1 BCAS causes global CBF decrease and hypoxia in mouse brain 
The CBF was recorded for 5-10 mins before the implantation of the 
microcoils and set to 100% as the pre-implantation baseline. At 15 min after 
bilateral implantation of the microcoils, CBF decreased to 62.8 ± 2.4% of 
pre-implantation baseline (Figure 3.1), indicating that coils successfully 
narrowed the carotid artery and reduced the global cerebral perfusion. As 




 Figure 3.1 rCBF in sham-operated and BCAS mice 
Reduction in relative cerebral blood flow (rCBF) at 15 min after bilateral 
implantation of microcoils to constrict the common carotid arteries.  CBF 
was expressed as percentage of the baseline level obtained pre-implantation. 
Bars represent mean ± S.E.M., N =11 per group. ***p < 0.005 by Student’s 
t-test, t = 7.6. 
 
Figure 3.2 showed the immunofluorescent intensity of HIF1-α enhanced 
significantly both in cortex and CC at 15 days after the surgery. Besides, 
Western blot revealed that HIF1-α increased to nearly 2-fold in CC (Figure 
3.3). HIF1-α expression shows strong evidence for a hypoxic response 





 Figure 3.2 Representative image of HIF-1α immunofluorescence in the 
brain at 15 days after BCAS 
A, Schematic diagram showing coronal section of the mouse brain at the 
level of 0.5-1 mm anterior to bregma. Green and red shaded rectangles 
indicate the representative images of CC region (upper panel) or cortex 
region (lower panel) shown in B. B, Left panel: Sham-operated, Right panel: 
BCAS. Scale bar = 60μm. Insets of right panel: images of higher 
magnification showing HIF-1α (green) staining co-localized with nuclei 
(stained with DAPI, blue). Scale bar =10 μm. Abbreviations: CC, corpus 




 Figure 3.3 Up-regulation of HIF-1α expression in white matter tissues 
following BCAS.  
A, representative immunoblot and B, bar graph of white matter tissue HIF-
1α immunoreactivity (as mean ± S.E.M. fold-change relative to mean value 
of sham animals), normalized to GAPDH. N=6, *p < 0.05 by Student’s t-test, 
t = 2.6. 
 
3.2.2 Selective White matter lesions induced by hypoperfusion 
Fifteen days after implantation, BCAS mice showed myelin loss 
characterized by the obviously reduced integrity of myelin sheaths and the 
intensity of myelinated fibres in BCAS mice in white matters such as the 
corpus callosum (Figure 3.4A) and internal capsule (Figure 3.4B), as 
revealed by Kluver-Barrera staining. The remaining fibres are apparently 
disordered with the appearance of vacuoles in the myelin sheaths. 
Furthermore, immunoreactivity of myelin basic protein (MBP) decreased by 
around 50% in WMT of BCAS mice (Figure 3.5). MBP is exclusively 
expressed in matured OLGs and thus is a marker for mature OLG. Both these 
observations are indicative of WML development following BCAS.  
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 Figure 3.4 Kluver-Barrera staining in white matter regions  
A, Representative images in CC of sham-operated mice (upper panel) and 
BCAS mice (lower panel). Panel on the right shows high magnification 
images of the areas defined by the red squares on the left panels. Schematic 
diagram shows coronal section of the mouse brain at the level of 0.5-1 mm 
anterior to bregma.  B, Representative images in internal capsule. Scale bars 
= 120 µm. Schematic diagram shows coronal section of the mouse brain at 




Figure 3.5 Down-regulation of MBP expression in white matter tissues 
following BCAS.  
A, representative immunoblot and B, bar graph of white matter tissue myelin 
basic protein (MBP) immunoreactivity (as mean ± S.E.M. fold-change 
relative to mean value of sham animals), normalized to β-actin. N=6,      
***p < 0.001 by Student’s t-test, t = 5.6. 
 
There were no apparent neuronal injuries in the cortex and hippocampus 
as shown by KB staining (Figure 3.6B and C respectively). 
Immunoreactivity of NeuN in cortex confirmed the observation of KB 
staining (Figure 3.7). From the above evidence, it is concluded that global 
chronic hypoperfusion caused selective WML without apparent cortical or 




 Figure 3.6  Kluver-Barrera staining in grey matter regions 
A, Schematic diagram showing coronal section of the mouse brain at the 
level of 1.3-1.8 mm posterior to bregma. Red and blue shaded rectangles 
show the areas of images shown in B (cortex) and C (CA1 hippocampus), 





Figure 3.7 Levels of NeuN in cortex of sham and BCAS mice.  
A, Representative immunoblots and B, bar graph of cortical NeuN 
immunoreactivity (as mean ± S.E.M. fold-change relative to mean value of 




3.2.3 Cognitive impairment in BCAS mice 
Barnes Maze, similar to Morris Water Maze and to the radial-arm maze, 
is a test for spatial learning and memory, where the mouse is placed into the 
maze and was allowed to find the escape box. More details of the 
experimental settings and procedures have been described in Chapter 2, 
section 4). It has a 3-day acquisition phase and a probe trial 24 h after 
acquisition phase. Primary latency (s) primary path length (cm) and primary 
errors are designated as the time, moving distance and pokes in wrong holes 
before the mouse reached the target hole for the first time (Sunyer et al. 
2007). They are commonly used to evaluate the whether  the mouse have 
learnt the task during the acquisition phase,  since it is assumed that mice 
that remember the location of the target hole will have a shorter latency and 
will search fewer holes by directly moving towards the target hole. Searching 
strategy is an important parameter to indicate if the mouse had learnt to solve 
the task with spatial memory. The search strategies can be defined into three 
categories: direct, serial or mixed (Definition of the three strategies has been 
described in Chapter 2, Section 4.5.1. Only direct strategy is considered that 
the mouse is using spatial memory (Sunyer et al. 2007). Therefore, searching 
strategy the mouse using to escape is an important indicator of its spatial 
memory as well. Barnes maze test was performed in mice at 15 days after 
surgery in this study.  
Barnes maze test was performed in mice at 15 days after surgery in this 
study. During 3-day spatial acquisition phase, the primary path length 
(Figure 3.8A), primary errors (Figure 3.8B) and primary latency (Figure 
3.8C) to the target hole decreased significantly (analysed by two-way 
89 
 
ANOVA with repeated measures) in both sham-operated and BCAS group, 
with F(2,16)=15.5, p<0.000, F(2,16)=6.1, p<0.05 and F(2,16)=14.7, p<0.000 
respectively, but there is no difference between the two groups of animals 
with F(1,8)=0.9, F(1,8)=1.4, F(1,8)=0.8 respectively. 
 
Figure 3.8 Barnes Maze performance of sham and BCAS mice during 
the acquisition phase  
Two-way ANOVA with repeated measures shows that these three 
parameters decrease in both sham and BCAS mice during three days of the 
acquisition phase with F(2,16)=15.5, p<0.000, F(2,16)=6.1, p<0.05 and 
F(2,16)=14.7, p<0.000 for  A, primary path length B, primary errors and C, 
primary latency respectively. N=9. Although the data show some separation 




 However, during the acquisition phase, the sham-operated mice showed 
increasing use of the direct searching strategy in favour of the serial mixed 
strategy (Figure 3.9A), suggesting that the sham-operated mice were relying 
more on their spatial memory to solve the task. On the other hand, the BCAS 
mice remained using mainly the serial strategy instead (Figure 3.9B).  
 
Figure 3.9 Searching strategies used by the sham and BCAS mice during 
acquisition phase 
A, Searching strategy of sham-operated mice B, Searching strategy of BCAS 
mice. Fisher’s exact test was used on the Day 3, showing a significant 





Fisher’s exact test shows that on the third training day, the searching 
strategies chosen by the mice were significantly associated with the group 
difference. These observations suggested that though sham-operated mice 
and BCAS mice have both learnt to escape from the maze during 3 days’ 
training, only sham-operated mice solved the task using spatial memory. 
BCAS mice improved their performance by searching the holes along the 
perimeters quickly instead of going directly to the target hole.  
Probe trial was conducted 24 h after the last section of acquisition phase 
to test the memory of the mouse. Mice were exposed to the Barnes maze 
with the target hole being covered and allowed to explore the maze for 2 
minutes. Setting of the 5 zones was demonstrated in Chapter 2, section 4.5.2 
as shown by Figure 2.3B. Two-way repeated ANOVA shown significant 
different preferences of the zones by sham and BCAS mice (Figure. 3.10A), 
F(2,16) = 5.3. Notably, sham-operated mice strongly prefer to stay in Zone 1 
where the target hole was located with the duration spent in Zone 1 being 
about 4-fold longer than the duration spent in any other zone (Figure 3.10A). 
In contrast, the time spent in Zone 1 by the BCAS mice was only about half 
of that of the sham-operated mice. Besides, Figure 3.10B showed that the 
BCAS mice made significantly more total errors than the sham-operated 
mice due to that BCAS mice tended to explore other holes, while sham-
operated mice preferred to stay around the target holes. These observations 
suggested that sham-operated mice had a better memory about the location 
of escape box while the BCAS showed a deficit memory. Searching strategy 
(before the mouse reaching the target hole for the first time) analysis showed 
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to similar to acquisition phase, sham-operated mice prefer direct strategy 
while BCAS mice remained using serial or mixed strategy (Figrue 3.10C). 
Therefore, it could be concluded that BCAS mice showed cognitive 
impairment characterized with impaired spatial memory.  
 
Figure 3.10 Barnes Maze performance in the probe trial  
A, Total time spent in Zone 1-5. Duration time in 5 zones were significantly 
different between sham and BCAS group, by two-way repeated ANOVA, F 
(2, 16) =5.3, p<0.05, N=9. B, Total error made during the 2 min of probe 
trial, *p<0.05 by student’s t test. N=9, t=2.2. C, Searching strategies for 
sham-operated and BCAS group. Fisher’s exact Test shows a significant 
association between the strategies and the group difference. P<0.05, N=9 per 
group. 
 
3.2.4 Lipids alterations 
3.2.4.1 Effects of hypoperfusion on sphingolipids 
The total amount of sphingolipid was not changed by hypoperfusion in 
BCAS. But significant reduction in the total amount of glycoceramides was 
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observed in WMT of BCAS as shown in Figure 3.11. The total amounts of 
Cer and SM did not appear to be affected by hypoperfusion (Figure 3.11). 
 
Figure 3.11 Changes in amounts of sphingolipids for cerebral WML 
The amounts major subclasses of sphingolipids, including Ceramide, 
sphingomyelin and glycoceramides (GlycoCer) are expressed as 
mean±S.E.M, normalized to the total protein concentration. *P<0.05 by 
Student’s t- test, t=2.2. N=6.  
 
 
 In glycoceramides profiling (Figure 3.12), monohexosylceramides 
(MHC) are shown to be the predominant components, which include both 
galactosylceramides (CalCer) and glucosylceramides (GluCer). On the other 
hand, the dihexosylceramides (DHC), which includes the lactosylceramides 
(LacCer), consist only less than 0.3% of total glycoceramides. Profiles of 
individual glycoceramides (Figure.3.12) showed a decreasing trend for all 7 
species analyzed here, though only MHC 22:0 and MHC 24:1 showed 




 Figure 3.12 Comparative glycoceramides profiles in WMT of Sham and 
BCAS 
Individual species of glycoceramides are expressed as mass fractions of total 
amount sphingolipids.  *P<0.05 by Student’s t- test, t=2.6 for MHC 22:0 and 
t=2.5 for MHC 24:1. N=6. Abbreviations: MHC, monohexolceramide; DHC, 
dihexolceramide. 
  
It is interesting that though the total amount of Cer and SM remained 
unchanged, the individual species compositions altered. As shown in Fig 
3.13, there were notable reductions in the mass fractions of Cer d18:1/C24:1, 
Cer d18:0/C24:0 and SM 42:1, while significant elevations in SM 34:1, SM 
36:1 were observed (Figure 3.14). When separating the sphingolipid species 
by the carbon numbers of their acyl chain, it is noted that the accumulative 
amount of C22, C24-sphingolipids decreased while C16, 18 increased 




 Figure 3.13 Comparative ceramides profiles in WMT of Sham and 
BCAS 
Individual species are expressed as mass fractions of sphingolipids total 
amount. *P<0.05 by Student’s t- test, t=2.8 for Cer d18:1/C24:1and t=2.2 for 





Figure 3.14 Comparative sphingomyelins profiles in WMT of Sham and 
BCAS 
Individual species are expressed as mass fractions of sphingolipids total 
amount. *P<0.05, **P<0.01 by Student’s t- test, t=2.4 for SM 34:1, t=3.6 for 
SM 36:1, and t=3.0 for SM 42:1, N=6. 
 
 
Figure 3.15 Changes of C16-18 sphingolipids and C22-24 sphingolipids 
in WML 
Data are expressed as mass fractions of total amount sphingolipids. **P<0.0 





3.2.4.2 Effects of hypoperfusion on phospholipids 
As shown by Figure 3.16, appreciable elevations in PS and PG in BCAS 
mice were found to be of statistical significance both at ~1.3 to 1.4-fold 
increase. The total amounts of LPC, PC, LPE, PE, PI did not appear to 
change. Since PC and PE are the predominant phospholipid subclasses, the 
amount of overall phospholipid also did not change.  All the 7 individual 
species of PS were elevated significantly (Figure 3.17A) and 2 species of PG 
(16:0/18:1; 18:1/18:1) increased notably (Figure 3.16B) in BCAS.  Most 
individual species, especially the predominant species of LPC, PC, LPE, PE, 
and PI remained unchanged. 
 
 
Figure 3.16 Changes in amounts of phospholipids for cerebral WML 
Amounts of individual subclasses were normalized to the total protein 
concentration. *P<0.05 by Student’s t- test, t=2.7 for PS and t=2.6 for PG, 
N=6. Abbreviations:  LPC, lysophosphatidylcholine; PC, 
phosphatidylcholine; LPE, lysophosphatidylethanolamine;  PE, 






 Figure 3.17 Profiles of PS and PG in WMT for Sham and BCAS mice 
A, Profile of PS, *P<0.05 by Student’s t-test, respectively PS 36:1, t=3.4; PS 
36:2, t=2.4; PS 38:3, t=3.0; PS 38:4, t=3.0; PS 38:5, t=2.5; PS 40:5, t=2.3, 
PS 40:6, t=2.3.  N=6.  B, Profile of PG, *P<0.05, t= 2.6 for PG 16:0/18:1; 




3.2.4.3 Effects of hypoperfusion on cholesterol  
As we can see from Figure 3.18, the cholesterol levels in sham-operated 
mice and BCAS mice were 21.8±1.3 and 21.7±1.3 µg/mg total protein 
respectively, suggesting that chronic hypoperfusion did not affect the 
cholesterol levels in WM. 
 
Figure 3.18 Amounts of total cholesterol in WMT for Sham and BCAS 
mice 
Amounts of cholesterol were normalized to total protein. No significance 




3.3.1 Hypoperfusion caused long-lasting hypoxia  
Cerebral hypoperfusion is usually quantified by CBF (D'Haeseleer et al. 
2015). In this study, the CBF was measured by laser-doppler flowmetry as 
described previously (Shibata et al. 2004). Shibata et al. have demonstrated 
that BCAS reduced the global CBF to a minimum (~70% of the baseline) 
two hours after the BCAS, which is close to our observation (62.8 ± 2.4%) at 
15 mins, and then the CBF slowly recovered by 10% at 14 days.  Hypoxia-
inducible factor 1(HIF-1) is a very important factor that respond to hypoxia. 
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Its alpha subunit (HIF-1α) level determines the transcriptional activity of 
HIF1. Under well-oxygenated conditions, HIF1-α is degraded rapidly by an 
ubiquitin ligase. While in hypoxic conditions, the degradation is inhibited 
and thus HIF-1α level raises, inducing down-stream gene transcription 
(Adams et al. 2009; Semenza 2012). Thus HIF-1α level is usually used as a 
marker for hypoxia. Chronic cerebral hypoperfusion in rats induced 
significant long-lasting HIF-1α accumulation in the brain has been 
demonstrated (Yang et al. 2013; Marquez-Martin et al. 2012), indicating the 
long-lasting hypoxic conditions induced by chronic hypoperfusion. Similarly, 
we also revealed significant immunofluorescent intensity increases of HIF1-
α both in cortex and CC as well as elevated HIF-1α protein level in WMT.  
Therefore, the reduced CBF and global elevation of HIF-1α at 15 days 
suggested BCAS has successfully induced cerebral chronic hypoperfusion 
and a long-lasting global hypoxic condition in cerebral WM. 
3.3.2 Selective white matter lesions 
WMLs in the brain appear as hypodensities on computed tomography or 
as hyperintensities in T2-weighted and proton density MRI(Pantoni and 
Garcia 1995).The neuropathological changes in these lesions are 
characterized by diffused myelin sheath rarefaction, loss of oligodendrocytes 
and glia activation (Englund 2002).  
Kluver-Barrera staining was firstly described by Kluver and Barrera 
(Kluver and Barrera 1953). It is a combined myelin stain by Luxol Fast Blue 
that has strong affinity for lipoproteins in myelin sheath and Nissl stain by 
cresyl violet. Under the stain, myelin fibres appear blue and Nissl substance 
and nuclei appear pink to purple.  It is widely used in studies involved with 
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white matters (Nakaji et al. 2006) (Huynh et al. 2014). MBP, exclusively 
expressed by mature OLG, is a major protein in myelin which accounts for 
about 30% of the total protein in CNS myelin (Quarles 2005). It plays an 
essential role in maintaining the compact myelin by adhering the cytoplasmic 
leaflets of the OLG membrane together, and thus reduced MBP indicated 
myelin damage and has been observed in demyelination diseases (Harauz 
and Boggs 2013). Therefore, our results demonstrate that BCAS induced by 
implantation of microcoils with an inner diameter of 0.18mm cause selective 
WML without apparent damage to cortical and hippocampus neurons as 
shown by crysel violet staining of KB staining in Figure 3.6 and immunoblot 
of NeuN  in  Figure 3.7, which is consistent with previous research (Shibata 
et al. 2004). More severe cerebral chronic hypoperfusion in mice induced by 
implantation smaller microcoils (inner diameter: 0.16mm), producing a 
reduction in CBF by ~70%, have been reported to cause infarcts and neuron 
loss in cortex and hippocampus (Shibata et al. 2004). Permanent bilateral 
CCAs occlusion in rat, also called ‘2-VO’, could produce a reduction in CBF 
by 50% -70% (Hainsworth and Markus 2008) and induce not only white 
matter lesions but also neuronal damage in CA3 hippocampus (Kawaguchi et 
al. 2002). These observations suggest that white matters are more vulnerable 
to mild chronic hypoperfusion. However, the reasons are not fully 
understood. One possibility is that WM receives most of its blood supply 
through long penetrating arteries from the surface of the brain and 
anastomoses between the penetrating arteries are scarce or absent. This lack 
of collaterals may cause the WM to be more sensitive to hypoperfusion 
(Pantoni and Garcia 1997b). Besides, OLGs are believed to be extremely 
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vulnerable to ischemia (Dewar, Underhill, and Goldberg 2003). Mechanisms 
of the OLG’s vulnerability are not fully understood yet. OLG is sensitive to 
oxidative stress due to its high lipid content, high iron and limited 
antioxidants (Juurlink, Thorburne, and Hertz 1998). Chronic hypoperfusion 
has been reported to induce oxidative stress in white matters (Miyamoto, 
Maki, et al. 2013). Therefore, the vulnerability to oxidative stress may 
contribute to OLG’s vulnerability to hypoperfusion. Thus, to better 
understand the pathological aspects and development of WML, it is 
important to study the lipidome and its alteration in WML induced by 
hypoperfusion. 
3.3.3 Cognitive impairment induced by hypoperfusion shown by 
Barnes Maze 
Although both sham-operated mice and BCAS mice showed clear 
reductions in the primary path length, latency and errors during acquisition 
phase, different strategies were preferred by the two groups, indicating that 
BCAS mice did not switch to a direct searching strategy as evidenced in the 
sham-operated mice (Figure. 3.9). This may suggest that BCAS mice learnt 
the fact that there was an escape box through training, but they had not learnt 
to locate the escape box with spatial cue or they may not remember precisely 
the location of the, and thus causing the failure to switch strategies. This is 
confirmed by the result that BCAS mice spent much less time Zone 1 where 
the target hole was located and tended to explore the wrong holes resulting a 
significant more total errors during probe trials. Though some studies have 
used primary latency to evaluate the performance in Barnes Maze (Yamada 
et al. 2011; Sunyer et al. 2007), Harrison et al. have also reported that escape 
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strategy is more informative than primary latency in assessing the 
performance in Barnes Maze (Harrison et al. 2006). Thus, it is reasonable to 
conclude that BCAS mice showed impairment spatial memory in this 
experiment. As we have demonstrated that only selective WML was induced 
in BCAS mice without neuronal injury in cortex or hippocampus, our results 
indicate that global chronic hypoperfusion causes cognitive impairment 
through WML, providing evidence that BCAS is suitable as an animal model 
in studying the mechanism and therapy to WML in vascular dementia.  
3.3.4 Sphingolipids alterations 
3.3.4.1 Reduction in glycoceramides  
In the present study, we have demonstrated all the sphingolipid species 
that are more than 0.1% of total mass fraction. Among the three major 
subclasses of sphingolipids, only glycoceramides showed a significant 
reduction of overall content due to the decreases of each individual species in 
WML. Lipid profiles of the white matters from the temporal cortex of 
patients with subcortical ischemic vascular dementia (SIVD) have been 
reported by Lam et al. (Lam et al. 2014), in which a similar reduction of 
GluCer and GalCer was indicated. It has been shown that the concentrations 
of glycoceramides in white matters and in myelin are respectively about 5-
fold and 10-fold higher than it is in grey matters (O'Brien and Sampson 
1965). Therefore, the reduction of glycoceramides is consistent with the 
expected myelin loss in WML of BCAS. Glycoceramides are important 
components of membrane structures, clustered in “lipid rafts” instead of a 
uniform distribution in the membranes (Westerlund and Slotte 2009). Due to 
their biophysical properties, decrease in glycosphingolipids in membranes 
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will increase the membrane fluidity (Curatolo 1987b). Thus they are crucial 
for the long-term stability of the tightly packed myelin sheaths (Curatolo 
1987a). GalCer is the predominant glycosphingolipid in myelin. GalCer is 
used as a marker for myelinating OLG as they are synthesised in parallel to 
the expression of MBP and PLP (Raff et al. 1978). Anti-CalCer antibodies 
reversibly inhibit the differentiation of OPC (Bansal and Pfeiffer 1989) 
(Ranscht, Wood, and Bunge 1987) and change organization of OLG 
membrane sheets in culture (Dyer and Benjamins 1988). These studies have 
suggested that CalCer plays essential role in the development of 
oligodendrocyte and myelination. When white matter damage occurs, OPCs 
respond quickly to proliferate, migrate and differentiate into myelin sheath-
forming, mature OLGs (Miyamoto et al., 2010). However, the extent and 
outcome of endogenous repair is limited in diseases with chronic WML 
(Alizadeh, Dyck, and Karimi-Abdolrezaee 2015). There is growing evidence 
that the failure to form new myelin sheaths due to disruption of OPC 
differentiation is one factor underlying chronic white matter damage 
(Alizadeh, Dyck, and Karimi-Abdolrezaee 2015) (Miyamoto, Maki, et al. 
2013; Miyamoto, Pham, et al. 2013). Therefore, reduced CalCer in BCAS 
may contribute to the WML by impeding OPC differentiation and 
remyelination as well, although further investigation is needed to elucidate 
this possibility.  
3.3.4.2 Acyl chain length alterations of sphingolipids 
C22-C26 and C16-C18 acyl chain sphingolipids have been defined as 
very long chain (VLC)-sphingolipids and long-chain (LC)-sphingolipids 
respectively according to previous studies (Spassieva et al. 2009)Imgrund, 
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2009 #248}. Although the overall amounts of Cer and SM were not 
significantly altered in WML, it is interesting to note the observed tendency 
of a decrease in VLC-sphingolipids an increase in LC-sphingolipids (Figure 
3.15). Similar changes have also been observed in the white matter tissues 
from the temporal cortex of SIVD patients (Lam et al. 2014). Besides, the 
lipidome of ceramides synthases 2 (CerS2)-null mice has been reported to 
have a similar profile with reductions in VLC-Cer and VLC-SM while 
elevated  LC-Cer and LC-SM and an overall reduction in hexosylCer in the 
brain, without significant variations in phospholipid and cholesterol. CerS2-
null mice exhibit intensive and progressive myelin and MBP loss (Imgrund 
et al. 2009). CerS2 belongs to a family of six ceramide synthases (CerS1-6). 
Each of the six CerS has their own preference for acyl-CoA when the acyl 
chain is introduced to sphingosine in the formation of ceramides. CerS2 is 
the enzyme that prefers VLC acyl-CoA (Laviad et al. 2008). Therefore it 
seemed that VLC-sphingolipid aberrations are associated with the myelin 
loss in WML in BCAS as well as WML in SIVD patients. Mechanisms of 
the demyelination pathologies induced by reduction of VLC are not 
understood. It is known that ceramide with different acyl chain lengths has 
different biophysical properties (Pinto et al. 2008). Similarly, LC-
sphingolipids have lower melting temperature, contributing to higher 
membrane fluidity (Niemela, Hyvonen, and Vattulainen 2006). It has been 
reported that depleting VLC-sphingolipids by depleting CerS2 caused 
biophysical property alterations such as fluidity and curvature, and 
morphology changes in cellular membrane in the brain, leading to 
compromised cellular processes(Silva et al. 2012).  
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Aside from the structural roles in cellular membrane and myelin, several 
sphingolipid species are also known as bioactive lipids that participate in 
various cell signalling pathways. Ceramide has been well reviewed for its 
role in regulating apoptosis. While Kroesen et al. showed that LC-Cer and 
VLC-Cer differentially regulate the apoptosis processes (Kroesen et al. 2003). 
Accumulation of LC-sphingolipids has been found to cause autophagy 
through arresting cell growth and inducing unfolded protein response 
(Spassieva et al. 2009), a cellular stress response related to the endoplasmic 
reticulum (ER) (Hetz 2012). Moreover, Zigdon et al. reported that depleting 
VLC-sphingolipid or exogenously added LC-ceramides could disrupt 
mitochondrial functions, inducing oxidative stress both in vivo and in vitro 
(Zigdon et al. 2013). Thus further studies are needed to elucidate how the 
alteration of acyl chain lengths associates with demyelination in WMLs.  
Besides, it is not clear that if CerS2 is involved in the WML with a vascular 
origin. Interestingly, Laviad et al.(Laviad et al. 2008) have observed that S1P 
specifically inhibited CerS2 activity non-competitively in vitro while having 
no effects on the other CerS (1, 3, 4, 5, and 6).  S1P has been known as an 
important bioactive sphingolipid in the past decade (Spiegel and Milstien 
2003). A number of studies have found that it was associated with the 
oligodendroglial lineage cell survival and development (Novgorodov et al. 
2007; Cui et al. 2014; Jaillard et al. 2005). This may imply the involvement 
of S1P in the sphingolipids changes of WML.  
3.3.5 Phospholipids alterations 
Phosphatidylserine (PS) is the third abundant subclass of phospholipids 
in mouse brain after PC and PE. In addition of its important role as a 
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structural component in biological membranes, regulating surface charge and 
protein localization (Yeung et al. 2008), PS has also been reported to act as 
modulators of several signalling pathways (Kim, Huang, and Spector 2014). 
PS is exclusively located at the inner side of the membrane bilayer in normal 
cells. Pathological conditions such as apoptosis induce the translocation of 
PS to the outside of the membrane bilayer (PS exposure), resulting in cells 
uptake and removal of the apoptotic cells via a PS-recognizing receptor on 
phagocytic cells (Zwaal, Comfurius, and Bevers 2005). PS is also a critical 
modulator for activation of Akt, Raf-1 and protein kinase C, supporting 
neuronal survival (Kim, Huang, and Spector 2014). Besides, PS modulates 
several receptors including the AMPA glutamate receptors, benzodiazepine 
receptors and cannabinoid type 2 receptors in relation to its function in 
regulating membrane surface potential (Kim, Huang, and Spector 2014). 
Interestingly, PS has been shown to stimulate both SphK1 and SphK2 
activity in Swiss 3T3 fibroblast lysates in a dose-dependent manner (Liu, 
Sugiura, et al. 2000) due to the PS binding sites in these kinases (Weigert et 
al. 2010). Mozzi et al. (Mozzi, Andreoli, and Horrocks 1993) have shown 
that hypoxia could induce PS synthesis in tissue slices or homogenates of rat 
cerebral cortex. A number of studies have observed PS exposure induced by 
hypoxia (Slone, Pope, and Fleming 2015) or hypoxic mimic agent CoCl2 
(Gotoh et al. 2012) (Karovic et al. 2007). Morever, PS elevation was also 
observed in the postmortem brain sample of SIVD patients (Lam et al. 2014). 
These observations suggest that the PS augmentation in WML of BCAS 
mice is associated with the hypoxia induced by hypoperfusion.  Two major 
routes for PS synthesis have been summarized: acylation of lysophosphatidyl 
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serine (LPS) via a lysophospholipid acyltransferase or base exchanging 
reactions with PE and PC in microsomes and phosphatidic acid-dependent 
pathway (Kim, Huang, and Spector 2014). Besides, direct decarboxylation of 
PS in mitochondria has been reported to contribute at least 7% of PE in the 
brain, which may be important in myelination in the early stages of brain 
development (Bradbury 1984). According to the result of LC-MS/MS 
analysis in this study, the content of PE or PC did not alter in WML under 
chronic hypoperfusion, thus the elevation of PS seemed to be associated with 
the acylation of LPS. LPS profiling should provide further useful 
information. 
Phosphatidylglycerol (PG) in mouse brain is actually quite low, 
consisting of 0.4-0.6% of total phospholipids according to our results. 
Consistently, lipidome of postmortem white matter tissues demonstrated an 
increase of PG in the SIVD patients compared to control cohort (Lam et al. 
2014). PG is reported to be exclusively component of mitochondrial 
membrane (Schenkel and Bakovic 2014). It can be formed by a transfer of 
the phosphatidyl moiety of PC to free glycerol (Sastry 1985).  PG is 
synthesised from phosphatidic acid via cytidine diphosphate diacylglycerol 
(CDP-DAG) and glycerol-3-phosphate (G3P) (Sastry 1985) and can be 
degraded back to DAG and G3P by PG specific phospholipase Pgc1p 
(Pokorna et al. 2015). Mutating Pgc1p in yeasts could induce PG 
accumulation that results in mitochondrial membrane fragmentation and a 
striking increase in mitochondrial respiration as indicated by a 2-fold higher 
O2 consumption as well as Complex IV (Pokorna et al. 2015). This suggests 
that it is essential to degrade excess PG in maintaining the morphology and 
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function of the mitochondrial membrane. Researches have shown that 
mitochondrial dysfunction is associated with demyelination diseases. For 
example, increased complex IV activity has been observed in a mouse model 
of hypomyelination induced by MBP gene knockout (Andrews et al. 2006), 
or in the white matter lesions of multiple sclerosis (Mahad et al. 2009). Loss 
of myelin sheaths is observed in primary mitochondrial diseases such as 
Kearns-Sayre syndrome and Leber's hereditary optic neuritis (Campbell and 
Mahad 2012). Chronic hypoperfusion has been shown to induce 
mitochondrial dysfunction (Du et al. 2013) (Guang and Du 2006).  However, 
it is not clear that how the mitochondrial dysfunction induced by 
hypoperfusion is associated with WML. Our observation of PG elevation in 
BCAS mice may provide a hint on the direction of future work.  
3.3.6 Unchanged cholesterol 
Cholesterol is well known for its role in myelin biogenesis because of its 
role in lipid rafts. Interference with cholesterol synthesis would results in 
defects of myelination (Mielke et al. 2005). In addition, depletion of 
cholesterol has been found in white matters of multiple sclerosis (MS) 
patients. The lipidomics study on the white matters of SIVD patients has also 
indicated a decrease in cholesterol. However, it is interesting to find that the 
overall level of cholesterol remained unchanged in the hypoperfusion-
induced WML. This might be due to that the white matter lesion in SIVD 
patients are more severe than the WML in the mouse model, suggesting that 
reduction in cholesterol may occur in a later stage of development of 
hypoperfusion-induced WML.  
3.3.7 Summary of lipid changes  
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It has been reported in this chapter that chronic cerebral hypoperfusion 
induced selective WML characterized by significant MBP loss, myelin 
sheaths rarefaction and vast alterations of the WM lipid including overall 
reduction of glycoceramides and sphingosine, VLC-sphingolipids decrease 
accompanied with LC-sphingolipids accumulation and elevations of PS and 
PG. Due to the distinct biophysical properties of myelin proteins and lipids, 
they form a delicate balance of forces maintaining the stable structure of 
normal myelin. Ohler et al. (Ohler et al. 2004) have depicted a physical 
model considering the forces, indicating that increases of myelin fluidity, 
decreases of myelin adhesion and increases of membrane curvature 
contribute to demyelination. These authors suggested that MBP and 
glycoceramides reduction could increase myelin fluidity; PS elevation could 
decrease the intermembrane adhesion because of their negative charges; the 
accumulation of LC-sphingolipids could increase the membrane curvature. 
Hypoperfusion induces lipid changes in WM that profoundly disturb the 
myelin structure stability and may interfere with signaling pathways 
involving bioactive lipids such as CalCer, PG, and thus results the WML 






CHAPTER 4 SPHINGOSINE KINASE 
INHIBITION AMELIORATES CHRONIC 
HYPOPERFUSION-INDUCED WHITE MATTER 
LESIONS 
4.1 Introduction 
OLGs form sail-like extensions of their cytoplasmic membrane which 
wrap around the axon up to 150 layers thick to form myelin sheaths. This 
process is dynamic even in the mature CNS where oligodendrocyte 
progenitor cells (OPCs) still persist (Nishiyama et al. 2009). When white 
matter damage occurs, OPCs respond quickly to proliferate, migrate and 
differentiate into myelin sheath-forming, mature OLGs (Miyamoto et al. 
2010). However, the extent and outcome of endogenous repair is limited in 
diseases with chronic WML (Alizadeh, Dyck, and Karimi-Abdolrezaee 
2015). There is growing evidence that the failure to form new myelin sheaths 
due to disruption of OPC differentiation is one factor underlying chronic 
white matter damage (Alizadeh, Dyck, and Karimi-Abdolrezaee 2015; 
Miyamoto, Maki, et al. 2013; Miyamoto, Pham, et al. 2013). In addition, a 
condition induced by prolonged CoCl2 incubation that mimicked chronic 
hypoxic state in primary cultured OPCs has been reported to cause HIF-1α 
stabilization in OPCs and inhibition of OPC maturation (Miyamoto, Pham, et 
al. 2013). Sphingolipids especially ceramide, sphingosine, and sphingosine-
1-phosphate (S1P) have been recognized as important regulators of cellular 
functions,   (Hannun and Obeid 2008). S1P was previously reported to act as 
a second messenger in cell proliferation (Olivera and Spiegel 1993) and an 
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anti-apoptotic messenger (Cuvillier et al. 1996). It has been reviewed that 
relative expression and activation of S1P receptors differentially regulate 
various physiological and pathological processes in the CNS such as 
ischemia (Hasegawa et al. 2010) and demyelination diseases (Matloubian et 
al. 2004). Previous reports have demonstrated the involvement of the S1P 
signalling pathway regulating OLG lineage-cell survival, proliferation, 
membrane dynamics and differentiation (Jung et al. 2007; Miron et al. 2008; 
Cui et al. 2014).However, little is known about the role of SphK/S1P 
signalling and FTY720 in hypoxia- or hypoperfusion-associated WML. 
Therefore, sphingosine and S1P and associated signalling pathways, 
including SphK and HIF-1α, in relation to the development of WML were 
measured using the BCAS model. Furthermore, the role of S1P on OPC 
differentiation into OLG was investigated in vitro using CoCl2 prolonged 
incubation to elucidate the possible roles of SphK/S1P/S1PR in 
hypoperfusion-induced WMLs   
 
4.2 Results 
4.2.1 Effects of SKI-II on BCAS-induced S1P changes  
Lipid extracts in WMT were analysed by LC-MS/MS. Four species of 
S1P, namely, S1P (d18:2), S1P (d18:1), S1P (d18:0) and S1P (d20:1), were 
uniformly increased with the total S1P level elevated (11.3±0.8 nmol /mg 
total protein) significantly by nearly 40% compared to sham-operated mice 
(8.1±0.2 nmol /mg total protein)  (Figure 4.1). It can be seen that d18:1 S1P 
is the predominant species. 
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 Figure 4.1 Effects of SKI-II on BCAS-induced S1P in WML 
S1P profiles of individual species in WML expressed as molar 
concentrations to total protein in Sham, BCAS (Vehicle) and BCAS with 
SKI-II treatment. One-way ANOVA F(2,16)=7.3 for S1P (d18:1) F(2,16)= 
6.9 for S1P (d18:0); F(2,16)= 6.7 for S1P (d20:1); F(2,16)=8.2 for total S1P, 




Figure 4.2 Effects of SKI-II on BCAS-induced sphingosine changes in 
WML 
Sphingosine profile of individual species in WM expressed as molar 
concentrations to total protein in Sham, BCAS (Vehicle) and BCAS with 
SKI-II treatment. One-way ANOVA F(2,16)=4.4 for Sph (d18:1) F(2,16)= 
8.5 for Sph (d18:0); F(2,16)=4.1 for total Sph, N=6. *P<0.05, **P<0.01 with 




Three species of sphingosine, namely Sphd 18:2, Sphd 18:1, Sphd 18:0 
was demonstrated in Figure 4.2. Sphd 18:1 and Sphd 18:0 decreased 
significantly in BCAS mice. On the contrary, Sphd 18:2 did not decrease in 
BCAS. Since Sphd 18:1 was the predominant species in cerebral WMT, the 
overall sphingosine in BCAS (32.3±1.8 nmol) diminished to ~77% of that in 
sham-operated mice (41.1±2.5 nmol /mg total protein).   
Not surprisingly, i.p. injection of the dual SphK1/SphK2 inhibitor SKI-II 
at a dose of 50mg/kg every other day abolished the BCAS-induced 
elevations in S1P as indicated in Figure 4.1. However, the BCAS-induced 
decreases in the levels of sphingosine were not affected by the treatment of 
SKI-II as shown in Figure 4.2.  
 
Figure 4.3 SKI-II treatment reversed WML and the loss of MBP in 
BCAS mice 
A, Representative images of Kluver-Barrera staining. Scale bars = 120 µm. 
Panel on the right show high magnification images of the areas defined by 
the black squares on the left panels, Scale bars = 30 µm. B, Representative 
immunoblot and C, bar graph of white matter tissue myelin basic protein 
(MBP) immunoreactivity (as mean ± S.E.M. fold-change relative to mean 
value of sham animals). One-way ANOVA, F (2, 16)= 9.7, *p < 0.05 with 
post-hoc Bonferroni correction. Veh =Vehicle. 
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4.2.2 SKI-II attenuates WML in BCAS mice  
 Furthermore, SKI-II partially attenuated the white matter damage as 
shown by the reductions in myelin loss and vacuolation in corpus callosum 
as shown by KB staining (Figure 4.3A) as well as partial recovery of MBP 
immunoreactivity (Figure 4.3B,C). 
4.2.3 Effects of SKI-II on BCAS-induced changes in SphK and 
oligodendroglial markers 
Interestingly, SphK2, but not SphK1 was up-regulated in BCAS, 
suggesting that SphK2 may be the main isoform responsible for the observed 
S1P increase (Figure 4.4A-C). Additionally, SphK2 increase was reversed by 
SKI-II treatment (Figure 4.4C). Levels of the proteoglycan NG2, a marker 
for OPCs known to be up-regulated after white matter damage (Nishiyama et 
al. 2009; Wigley et al. 2007) was increased in BCAS, but attenuated in 
BCAS with SKI-II treatment (Figure 4.4A and 4.4D). Taken together with 
the previously described changes in MBP (see Figure 4.3C,D), present 
results suggest that BCAS may disrupt the differentiation of OPC to mature 
oligodendrocytes, and that co-treatment with SKI-II restores this maturation 
process (characterized by decreasing NG2 and increasing MBP (Miyamoto, 
Pham, et al. 2013; Polito and Reynolds 2005)). On the other hand, the up-
regulation of hypoxia marker HIF-1α in BCAS was not affected by SKI-II, 
suggesting that S1P and SphK changes are downstream of HIF-1α-mediated 




 Figure 4.4 Effects of SKI-II on BCAS-induced changes in sphingosine 
kinase, NG2 and HIF-1α immunoreactivities. 
A, Representative immunoblots and bar graphs (as mean ± S.E.M. fold-
change relative to mean value of sham operated animals) of B, SphK1; C, 
SphK2; D, NG2 and E, HIF-1α immunoreactivities, N = 5 per group. One-
way ANOVA, F (2,12)= 0.8 (SphK1); 8.2 (SphK2); 11.0 (NG2); and 5.7 
(HIF-1α), *p < 0.05, **p < 0.01 and ***p < 0.005 with post-hoc Bonferroni 
correction. 
 
4.2.4 SKI-II attenuates the inhibition of OPC differentiation by 
hypoxia-mimetic CoCl2 in vitro 
To further investigate the involvement of HIF-1α-SphK in regulating 
OPC differentiation, SKI-II was added to cultured rat primary OPC in 
chemical hypoxia induced by CoCl2 as described previously (Piret et al. 
2002). OLG differentiation was induced by switching OPC medium to OLG 
medium as described in Chapter 2.  CoCl2 or SKI-II was added accordingly 
to OLG medium for treatment.  
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 Figure 4.5 Effects of SKI-II on OPC and OLG under non-hypoxic 
conditions 
Representative phase contrast images of A, OPC and B, OLG treated with 
vehicle DMSO and 0.2 µm SKI-II for 72 h. Upper panels: 10X 
magnifications, scale bar= 50μm. Lower panels: 40X, scale bar =10 μm. 
 
Figure 4.5A shows the phase contrast images of OPC treated with the 
existence of 0.1% vehicle (DMSO) alone or 0.2µM SKI-II under normal 
condition. OPC incubated with control or vehicle medium showed typical 
bipolar or tripolar morphologies for OPC. It can be seen that SKI-II 
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treatment for 72 h under non-hypoxic conditions caused the outgrowth of the 
OPC to diminish. After swifting the OPC medium to OLG medium and 
incubated for 72 h, the OPC differentiated into OLG, showing the typical 
multiple processes morphology for OLG (Figure 4.5B). Similarly, high cell 
death was observed with OLG treated with SKI-II. These results suggest that 
SphK activities are essential for the survival and development of OPC and 
OLG.  
On the other hand, hypoxic conditions induced by CoCl2 (up to 50µM) 
for up to 72 h did not have any significant effects on cell viability of OPC 
(Figure 4.6).  
 
Figure 4.6 OLG cell viability measured by MTT assays 
After treatment with CoCl2 (up to 50 µM) for 72 hours (p > 0.05 for all 
concentrations compared to untreated, one-way ANOVA with post-hoc 




However, increase in HIF-1α was evident as shown by the average 
intensity of HIF-1α immunofluorescence staining in cells treated with 25 µM 
CoCl2 (Figure 4.7).  
 
Figure 4.7 HIF-1α levels in OLG treated with CoCl2 in vitro 
A, top: representative HIF-1α immunofluorescence (IF) staining (red) in 
untreated and CoCl2-treated (25 µM, 72 h) OPC. Scale bar = 50 µm. Bottom: 
Higher magnification IF images of HIF-1α, DAPI and merged. Scale bar = 
10 µm. B, Quantification of HIF-1α immunostaining intensity with the cell 




Moreover, immunoblots of SphK2 in primary OPC incubated with OLG 
medium together with CoCl2 (25 µM) for 72 h increased to ~1.5 fold 
compared with incubation cells in the control OLG medium, suggesting that 
HIF-1α could stimulate the SphK2 expression in primary OLG (Figure 4.8).  
 
Figure 4.8 Effect of hypoxia on SphK2 expression in OLG in vitro 
A, Immunoblots and B, bar graphs (as mean ± S.E.M. fold-change relative to 
mean value of control) of SphK2 in oligodendrocytes (OLG) after treatment 
with CoCl2 (25 µM) for 72 h. *P<0.05 by student’s t-test, t= 3.9, N=3. 
 
 
Figure 4.9A showed the immunofluorescence staining of OPCs (NG2-
positive cells, green) and OLGs (MBP-positive cells, red). The ratio of OLGs 
to OPCs in hypoxic conditions induced by treatment with 25 µM CoCl2 were 
obtained and shown in Figure 4.9B. Hypoxia caused the OLG/OPC ratio to 
fall by more than half, indicating that hypoxia inhibited OPC differentiation 
into OLG. SKI-II (0.1 or 0.2 µM) was able to reverse this inhibition 
concentration dependently and completely at the higher concentration. These 
results strongly suggested that under hypoxic conditions, HIF-1α-induced 




 Figure 4.9 Effects of SKI-II on inhibition of OPC differentiation by 
hypoxia-mimetic CoCl2 in vitro  
A, Merged IF representative images for NG2 (green, marker for OPC), MBP 
(red, marker for OLG) and DAPI (blue, nucleus) in untreated and CoCl2-
treated cells with and without co-treatment with SKI-II, Scale bar = 30μm. B, 
ratio of OLG (MBP+ cells in E) to OPC (NG2+ cells after 72 h treatment 
(The method of quantification has been descried in Chapter 2). F (3, 16) = 
25.0 by One-way ANOVA with post-hoc Bonferroni’s tests (compared with 





Here, the profiles of sphingosine and S1P in the normal mice brain under 
hypoperfusion condition were revealed for the first time. Although S1P and 
sphingosine are present in relatively small amounts in the brain when 
compared to other sphingolipids and phospholipids, they are two important 
bioactive sphingolipids that are gaining more and more attention in the past 
20 years. A number of studies have reported an overall S1P elevation in 
ischemic or hypoxic conditions. Schnizer et al. found that S1P was induced 
significantly in A549 cells following hypoxia for 2-4 h (Schnitzer et al. 
2009). A similar elevation of S1P in microendothelial cells subjected to 
oxygen-deprivation (OD) was observed by Fernando et al. (Testai et al. 
2014). Sphingosine is an important intermediate, providing the backbone of 
most sphingolipids. Sphingosine kinases (SphK) catalyse the ATP-dependent 
phosphorylation of sphingosine and produce S1P. SphK is critical to the 
regulation of S1P levels (Spiegel and Milstien 2003; Pulkoski-Gross, 
Donaldson, and Obeid 2015). The elevated expression of SphK2 in BCAS 
mice (Figure 4.4C) was shown in this study, which explained the increase of 
S1P and reduction of sphingosine.  
SKI-II has been shown to be a SphK1/SphK2 dual inhibitor with a 
slightly higher potency towards SphK2 (IC50=20µM) than towards SphK1 
(IC50 =35µM) (Gao et al. 2012). X-ray crystallography revealed that SKI-II 
binds to the sphingosine binding site (Gustin et al. 2013), which explains that 
it shows no inhibition towards other kinases such as ERK2 or PKC-α 
(French, Schrecengost et al. 2003). Recently Cingolani et al. (Cingolani et al. 
2014) found that SKI-II inhibits dihydroceramide desaturase (Des1) activity 
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at a concentration of 10µM without reduction in Des1 protein, resulting in an 
accumulation of dihydroceramides in HGC 27 cells. The concentration of 
10µM SKI-II that exhibits Des1 inhibition is actually quite high compared to 
its usual concentration of 0.3 - 1µM applied to inhibit SphKs in primary 
culture of neurons (Yung et al. 2012) or in bronchial epithelial cell line 
(Mercado et al. 2014). In fact, IC50 concentration of SKI-II in JC cells is 
below 1µM (French et al. 2006). These observations suggest that though 
SKI-II might inhibit Des1 at high concentration, it is still reasonably 
acceptable as a selective SphKs inhibitor considering the low concentration 
we used for SphK inhibition. Besides, we have not observed any 
accumulation of dihydroceramides in WML under chronic hypoperfusion in 
vivo, and thus it is highly unlikely that Des1 was inhibited by SKI-II at the 
low concentrations used in these experiments.  Moreover, SKI-II has already 
been shown to have SphK inhibitory effects in mouse kidneys (Kim et al. 
2007), airway smooth muscles (Chiba et al. 2010), and the brain (Yung et al. 
2012) when administered either by i.p. injection or oral gavage. Thus, it is 
suitable to use SKI-II in the present study as a SphK inhibitor. And indeed 
SKI-II reversed the S1P and SphK2 elevation in WML. Notably, SKI-II did 
not significantly induce the sphingosine recovery though a slight increase 
could be seen. This may be due to the large discrepancy between the 
physiological amounts of sphingosine and S1P. Besides, the level of 
sphingosine is also regulated by CerS which synthases ceramides from 
sphingosine. 
We observed that SphK2, not SphK1, increased significantly in white 
matter extracts during global hypoperfusion, which explains the S1P 
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elevation in white matter lesions. Besides, a similar SphK2 elevation in 
hypoxic-mimetic primary OLG culture (Figure 4.8). Given that chronic 
cerebral hypoperfusion induced hypoxia as indicated by increased HIF-1α 
expression, our finding that hypoperfusion induces SphK2 expression is 
consistent with previous findings (Wacker, Park, and Gidday 2009; Yung et 
al. 2012) that brain SphK2 protein expression and activity were up-regulated 
in mice subjected to hypoxic preconditioning, while SphK1 remained 
unchanged. Schnizer et al. (Schnitzer et al. 2009) also reported the same in 
A549 lung cancer cells.  
Therefore, the effects of attenuated WML and S1P by the non-isozyme-
specific SKI-II may be mediated mainly via the inhibition of SphK2, but 
follow-up confirmatory studies with SphK2-specific inhibitors are needed. It 
is also unclear as to why expression of SphK2, but not SphK1 was affected 
by BCAS and SKI-II treatment. Though the two isozymes SphK1 and SphK2 
share five conserved domains, they differed in their N terminus and have 
different kinetic properties, distribution and certain opposing functions 
(Bryan et al. 2008; Liu, Sugiura, et al. 2000; Maceyka et al. 2005). SphK2 
has several transmembrane domains and also nuclear localization signal at its 
N terminus. Thus Sphk2 can be expressed in the cellular membrane, cytosol 
and nucleus in cell type-specific manners (Bryan et al. 2008). Compared to 
SphK2, SphK1 lacks the transmembrane domain and thus has mainly a 
cytosolic localization (Bryan et al. 2008). SphK1 has been reported to pro-
survival effects, while SphK2 is known to inhibit cell growth, induce 
apoptosis, and is upregulated in metabolically stressful conditions such as 
serum starvation (Liu et al. 2003; Maceyka et al. 2005).  Another possible 
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explanation of the selective up-regulation of SphK2 expression in BCAS is 
that SphK2 is the predominant isoform in the brain over SphK1 (Blondeau et 
al. 2007) and therefore the more functionally “active” form. Further 
investigations are needed to elucidate the basis for the isoform-specific 
changes in SphK2 under hypoxic conditions.  
Contrary to findings in this study that SKI-II attenuated the up-regulation 
of SphK2 activity under hypoxic conditions without reducing the expression 
of SphK1 in vivo or in vitro, a few studies reported that 10µM SKI-II not 
only inhibits SphK1 activity but also reduces the protein expression by 
enhancing the degradation of this enzyme via an ubiquitin-proteasomal 
pathway and/or activation of the proteasome in various cell lines (Cingolani 
et al. 2014; Loveridge et al. 2010; Ren et al. 2010). The reason why SphK1 
expression was not reduced in the present study may due to a number of 
differences in experimental systems, for examples, differences between rat 
primary oligodendrocyte cultures and immortalized cell lines; possible 
differences in the relative expression of SphK1 and SphK2 in these cells; as 
well as differences in the general experimental conditions. 
The present data indicated that with a dose of 50mg/kg intraperitoneally 
injected every other day, SKI-II only partially inhibits the SphKs, reversing 
the S1P elevation to the normal physiological level in vivo. Treatment with 
0.2 µM SKI-II for 72 h was able to partially inhibit the CoCl2-induced 
SphK2 up-regulation. However the mechanism of how SKI-II reduces 
SphK2 protein level remains to be elucidated. It has been reported that in 
common with SphK1, SphK2 was also regulated by the ubiquitin-
proteasomal pathway (Lim et al. 2011). Therefore it is possible that SKI-II 
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induced increase in SphK2 degradation via the similar ubiquitin-proteasomal 
pathway, although further work is required to confirm the presence of this 
process in the brain, as it may not occur in all cell types (Watson et al. 2013). 
It is not surprising that HIF-1α was found to be involved in the 
S1P/SphK signalling pathways in hypoxic conditions. Wacker et al. (Wacker, 
Perfater, and Gidday 2012) reported that chemical induction of HIF-1α was 
protective against ischemic injuries in SphK2+/+ mice but was ineffective in 
SphK2-/- mice. This is consistent with the current findings which show that 
BCAS-induced HIF-1α was not affected by SKI-II (Figure 4.4). The HIF-1α 
stabilizer CoCl2 induced SphK2 elevation in vitro (Figure 4.8) indicating that 
HIF-1α signals upstream of SphK. CoCl2 is a hypoxia-mimetic agent which 
can stabilize HIF-1α by inactivating the prolyl hydroxylases through binding 
to the iron-binding centre of the enzyme and blocking HIF-1α binding with 
pVHL(Yuan et al. 2003).  However, Yung et al. (Yung et al. 2012) found 
that isoflurane preconditioning induced HIF-1α only in SphK2+/+ but not the 
SphK2-/- mice, suggesting potentially complex, bi-directional regulation 
between HIF-1α and SphK, similar to those found for SphK1 in cancer cells 
(Anelli et al. 2008; Anelli et al. 2005). Further work is therefore required to 
elucidate the molecular pathways underlying HIF-1α and SphK regulation. 
 In addition to astrocytes, microglia and oligodendrocytes, there exists 
another glial cell population that is characterized by the expression of NG2 
(Ong and Levine 1999). NG2-positive cells, also known as polydendrocytes, 
have the potential of proliferation or differentiation into mature OLG 
(Nishiyama 2007; Ong and Levine 1999). Although NG2 cells are reported 
to have astroglial fate and neuronal fate as well, the astrogenic and neuronal 
127 
 
potential is limited to a subset of embryonic NG2 cells (Huang et al. 2014). 
In adult CNS, cells express PDGFRα also express NG2 (Dawson et al. 2003). 
In addition, progeny of NG2 cells in white matters are either polydendrocyte 
or OLG (Nishiyama et al. 2009). As NG2 cells differentiate into mature OLG, 
they stop expressing NG2 and begin to express oligodendrocyte myelin 
antigens such as O4 and MBP. Therefore it is now widely accepted to use 
NG2 as a marker for oligodendrocyte progenitor cells (OPCs).  OPCs are 
activated rapidly in response to various demyelinating injuries. They 
proliferate and migrate to the lesion areas (Polito and Reynolds 2005). OPC 
number decreases upon onset and progression of remyelination concomitant 
with appearance of BrdU+ mature oligodendrocytes have been reported 
(Watanabe, Toyama, and Nishiyama 2002; Reynolds et al. 2002), suggesting 
at least a part of OPCs differentiation into mature OLG. However the extent 
and outcome of endogenous remyelination may be limited in chronic WML. 
There is growing evidence that the failure to form new myelin sheaths due to 
disruption of OPC differentiation is one factor underlying chronic white 
matter damage (Alizadeh, Dyck, and Karimi-Abdolrezaee 2015; Miyamoto, 
Pham, et al. 2013). It has been presently demonstrated, both in chronically 
hypoperfused BCAS mouse brains as well as in cultured cells treated with 
the hypoxia-mimetic CoCl2, that these conditions result in decreased MBP 
and increased NG2 .Furthermore, co-treatment with SKI-II was able to 
reverse MBP and NG2 alternations in both BCAS brains (Figure 4.3, 4.4) 
and CoCl2–treated cells (Figure 4.9). These data, taken together with 
observations of SKI-II’s amelioration of BCAS-induced WML (Figure 4.3) 
and S1P (Figure 4.1), as well as data from previous studies showing 
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disrupted OPC differentiation in chronic white matter damage (Alizadeh, 
Dyck, and Karimi-Abdolrezaee 2015) (Miyamoto, Maki, et al. 2013; 
Miyamoto, Pham, et al. 2013) strongly suggest that one mechanism 
underlying hypoperfusion-related WML is the inhibition of OPC 
differentiation induced by elevated S1P levels.  
More recently, S1P receptors have been described (Spiegel and Milstien 
2002). These receptors are all G protein-coupled receptors, which exist in 5 
subtypes namely S1P1-S1P5. It has been reported that cultured OPCs and 
OLGs expressed S1P1, S1P2, S1P3, S1P5 (Yu et al. 2004; Novgorodov et al. 
2007). Table 4.1 shows some previous publications about complex functions 
of S1P receptors in different stages of oligodendroglial lineage cells. 
FTY720P is a potent agonist for S1P1, S1P3, S1P4, S1P5.  It has been reported 
that FTY720P inhibited rat OPC differentiation into OLG at concentrations 
0.1-1µM for 72h while a low concentration of 10nM led to an increase in the 
percentage of mature OLG (Jung et al. 2007). However, the effect of 
FTY720P on OPC differentiation seems to be controversial.  Hu et al. (Hu et 
al. 2011) reported that 10nM FTY720P inhibited OPC maturation as evident 
by the retraction of oligodendrocyte processes and promote the proliferation 
during 98h of treatment. Additionally, S1P5 receptor activation has been 
reported to impede OPC migration (Novgorodov et al. 2007) and regulate 
process retraction in pre-oligodendrocytes (Jaillard et al. 2005), both of 
which may hinder OLG terminal differentiation and therefore attenuate 
remyelination after white matter injury (Keirstead and Blakemore 1999). In 
contrast, the S1P1-specific agonist SEW2871 seemed to have no effect on 
OPC differentiation (Jung et al. 2007). According to them, S1P1 is related 
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with promoting OPC proliferation via PDGF-induced mitogenesis of rat 
OPC (Jung et al. 2007). However, a very recent study showed that S1P1 
receptor knockout led to delayed maturation of mouse pre-OLG to OLG 
(Dukala and Soliven 2016). These controversial seem to indicate that S1P 
receptors may have different roles in different stages of oligodendroglial 
lineage cells. Results in the present study have clearly showed that the 
terminal differentiation of OPC was disrupted by SphK-induced S1P 
elevation. However, current data and previous publications mentioned above 
are not enough to determine the role of specific S1P receptors in hypoxia-
induced OPC differentiation disruption. Therefore receptor specific agonist 
or antagonist may provide further understanding of S1P signalling pathway 
in hypoxia-induced OPC differentiation disruption in future studies. 
Table 4.1 Function of S1P receptors in oligodendroglial lineage cells 
Receptor Function Reference 
S1P1 Promotes OPC proliferation Jung et al, 2007 
 Morphological maturation and early myelination Dukala et al, 2016 
S1P5 Promotes the survival of mature rat OLG  Jaillard et al, 2005 
 Inhibits OPC migration  Novgorodov et al, 
2007 
 Regulates process retraction in pre-OLG Miron et al, 2008 
FTY720P* Enhances OPC differentiation at low concentration, inhibits OPC 
differentiation  at high concentration 
Jung et al, 2007 
 Promotes the proliferation but  inhibites the differentiation Hu et al, 2011 
* FTY720P, a potent agonist of S1P1, S1P3, S1P4 and S1P5   
 
   As shown in Chapter 3, hypoperfusion caused a reduction of VLC-
sphingolipid and an increase of LC-sphingolipid (Figure 3.15). CerS2 was 
the enzyme that synthases VLC-ceramides. S1P has been reported to 
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specifically inhibited CerS2 activity non-competitively in vitro while having 
no effects on the other CerS (1, 3, 4, 5, and 6) (Laviad et al. 2008). 
According to this publication, there are two S1P1 receptor-like motifs in 
CerS2. The corresponding residues in S1P1 were identified as essential for 
S1P binding. Mutation either of the two S1P1 receptor-like residues in CerS2 
abolishes the S1P inhibition without affecting CerS2 activity (Laviad et al. 
2008). Thus, the current observation of elevated S1P levels may explain the 
acyl chain length alteration in WML, suggesting again the involvement of 
CerS2 in hypoperfusion. However, further investigations on the interplay 
between the elevation of S1P and alteration of sphingolipids induced by 
hypoperfusion are needed. 
In summary, the data presented in this chapter show that chronic 
hypoperfusion-induced WML and associated disruption of OPC 
differentiation may involve HIF-1α/SphK2/S1P/S1PR and that the SphK 
inhibitor, SKI-II, can ameliorate the WML along with hypoperfusion-
induced changes in S1P, SphK2 and OPC differentiation without affecting 
HIF-1α levels. SphK / S1P may be potential targets for the treatment of 
ischemic white matter disease. 
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CHAPTER 5 CONCLUSION, LIMITATIONS 
AND FUTURE WORKS 
5.1 Conclusion 
I have presented in this thesis data that demonstrated that chronic 
hypoperfusion induced by BCAS causes global CBF reduction in the mouse 
brain, leading to cerebral WML characterized by myelin loss, MBP reduction 
and OPC activation without apparent damage to cerebral grey matters. These 
BCAS mice showed deficits in learning and spatial memory as indicated by 
worse performance in a spatial memory test (Barnes Maze) when compared 
to the sham-operated mice. There are also changes in the lipidomes of 
cerebral white matters in the BCAS mice. Of the lipid molecules belonging 
to the 3 major lipid classes, namely sphingolipids, phospholipids and 
cholesterols, there are overall content reductions in glycosphingolipids and 
sphingosine but increases in S1P, PS and PG. More detailed analysis showed 
that the sphingolipid composition in the white matters altered with a 
reduction in very long acyl chain-sphingolipids whereas and an elevation in 
long acyl chain-sphingolipid. Cholesterol levels in white matters remained 
unchanged in the BCAS mice. These lipid alterations may affect the 
biophysical properties of the cellular membrane and thus may introduce 
instability in the myelin structure. Besides, lipid alterations are mainly 
observed in sphingolipids, indicating the essential roles of sphingolipids in 
maintaining WM integrity.  
In addition, the data revealed that a HIF-1α/SphK2/S1P signaling 
pathway is involved in chronic hypoperfusion-induced WML. Global 
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chronic hypoperfusion increases SphK2 activity and expression via 
stabilizing HIF-1α, resulting notable S1P elevation in white matter tissues. 
Chemical hypoxia induced by HIF-1α stabilizer CoCl2 in primary OPC 
culture also can cause elevation of SphK2 and impede OPC differentiation in 
vitro.  SKI-II, an inhibitor of SphK, can both attenuate the WML in vivo and 
release the inhibition of OPC differentiation in vitro, suggesting that 
SphK2/S1P activation in WML impairs the endogenous remyelination in 
response to white matter injury through the disruption OPC differentiation 
into OLG. Figure 5.1 shows a summary diagram of the main findings for this 
whole study. 
Collectively, chronic hypoperfusion induces an explosion of lipid 
alterations in white matters which may affect myelin stability resulting in 
demyelination and WML. Hypoperfusion activates HIF-1α/SphK2/S1P 
signaling contributing to WML through disrupting myelin repair and 
sphingolipid metabolism. Therefore, the data suggest that SphK / S1P may 
be potential targets for the treatment of ischemic WML. 
 





5.2 Significance  
Firstly, this study has demonstrated the lipidome of hypoperfusion-
induced WML in mouse for the first time. Characteristics of the lipidome of 
hypoperfusion-induced WML in mouse have been shown to be similar with 
the cerebral white matter lipidome in SIVD patients (Lam et al. 2014). 
Alterations in several structural lipids as well as bioactive lipids such as PS, 
PG, ceramide, sphingosine and S1P have been shown. Therefore, it provides 
valuable references for future studies in WML. Secondly, although previous 
studies have demonstrated the involvement of S1P and its receptors in 
regulating oligodendroglial lineage cells(Jung et al. 2007; Miron et al. 2008; 
Dukala and Soliven 2016) and that hypoxia induces inhibition of OPC 
differentiation (Miyamoto, Pham, et al. 2013), this study showed that 
hypoxia-induced inhibition of OPC differentiation is mediated via HIF-
1α/SphK/S1P pathway for the first time. Thirdly, SphK inhibition has been 
indicated to ameliorate hypoperfusion-induced WML in mouse. Though a 
dual SphK1 and SphK2 inhibitor SKI-II was used in this study, it has been 
shown that only SphK2 is up-regulated by hypoxia in the brain, which is 
consistent with previous report that SphK2 is the predominant isoform in the 
brain (Blondeau et al. 2007). ABC294640 is a selective SphK2 competitive 
inhibitor(Gao et al. 2012). It also has oral bioavailability in a rat model of 
diabetic retinopathy (Maines et al. 2006).  ABC294640 exhibits anti-tumour 
activity in various types of cancer cells due to SphK2 inhibition(French et al. 
2010; Beljanski, Knaak, and Smith 2010) and  is now in the early-phase 
clinical trial under the name YELIVA for treating solid tumor. Recently the 
RedHill Biopharma announced positive top-line results that YELIVA 
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successfully met its primary and secondary endpoints, demonstrating that the 
drug is well tolerated and can be safely administered to cancer patients at 
doses that provide circulating drug levels that are predicted to have 
therapeutic activity Therefore, YELIVA has clearly demonstrated that 
specific SphK2 inhibition may have potential in the treatment of ischemic 
WML.   
5.3 Limitations and Future works 
However, there are several limitations of the present study. We did not 
distinguish the GluCer and GalCer when analyze the glycoceramides. Except 
for the structural role of CalCer in myelin membrane, it is reported to 
regulate OPC differentiation and thus play a role in the development of 
oligodendrocyte and myelination (Bansal and Pfeiffer 1989; Ranscht, Wood, 
and Bunge 1987). To investigate GalCer alterations in WMLs could provide 
a better understanding of WML pathology and mechanisms. In addition, 
sulfatide or 3-O-sulfogalactosylceramide, is an important subclasses of 
sphingolipids in myelin. Although less abundant than GalCer, it accounts for 
up 4% of total myelin lipids (Takahashi and Suzuki 2012) and is exclusively 
expressed in myelin (Kirschning, Rutter, and Hohenberg 1998). Sulfatide has 
been reported to negatively regulate the oligodendrocyte terminal 
differentiation (Hirahara et al. 2004) and enhance oligodendroglia cell 
proliferation (Shroff et al. 2009). Therefore, inclusion of sulfatide will be an 
improvement in the lipidomic study.  
Although only SphK2 expression was observed to be up-regulated in 
hypoperfusion, the involvement of SphK1 cannot be completely excluded. 
Several studies have shown that SphK1 can be activated during hypoxia 
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(Anelli et al. 2005; Schwalm et al. 2008). Moreover, SphK1 and SphK2 are 
reported to have opposite functions in sphingolipid metabolism (Maceyka et 
al. 2005). However, SKI-II is a dual inhibitor of both SphK1 and SphK2. 
Therefore, in order to elucidate the specific roles played by SphK1 and 
SphK2 respectively in ischemic WML, selective SphK inhibitor can be used 
in future work. CB5468139 or SKI-I, is a potent selective SphK1 inhibitor 
with a Ki of 0.3 µM which decreased kidney adenocarcinoma A498 
proliferation (Gao et al. 2012). ABC294640 is a selective SphK2 competitive 
inhibitor with a Ki of 7.3µM (Gao et al. 2012). No effect was observed on 
SphK1, or the closely related diacylglycerol kinase, at concentrations up to 
100 µM (French et al. 2010). 
 CerS2 is the enzyme that prefers VLC-CoA to synthesize VLC-
ceramides in mammals. It is a key enzyme in ceramides metabolism and 
myelin formation. Cers2-/- mice show severe myelin defects in cerebral white 
matters, characterized with the reduction of VLC-ceramides, accumulation of 
LC-ceramides and thus showing severe myelin defects in cerebral white 
matters (Imgrund et al. 2009). Since a decrease of VLC-sphingolipids and an 
increase of LC-sphingolipids have been demonstrated in this study (Chapter 
3), it is interesting to investigate if the acyl chain length alteration in 
sphingolipids is related to CerS2.  
Sphingolipid metabolism is complex. Bioactive sphingolipid molecules 
and related enzymes can regulate the level of other sphingolipids. For 
example, degradation of S1P by Spl is the only exit point of sphingolipid 
metabolism. SphK1 and SphK2 have been found to regulate ceramide 
biosynthesis oppositely (Maceyka et al. 2005). Besides, S1P can inhibit 
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CerS2 activity and thus affect ceramide composition (Laviad et al. 2008). As 
demonstrated, SKI-II partially reverses the sphingolipids chain length 
alterations in WML but more work is needed in order to understand the 
mechanism of SphK/S1P in hypoperfusion-induced sphingolipid changes.  
In addition, mitochondrial dysfunction may possibly be involved in the 
pathophysiology of WML as indicated by the PG elevation and LC-
sphingolipid accumulation. Thus, it will be interesting to investigate the 
relationship between lipid changes and the alteration of mitochondria 
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